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Star-shaped cells called astrocytes are a common cell type in the brain. They 
have a number of roles that are important for the health of surrounding nerve-
cells (called neurons). However, the factors that control astrocyte functions are 
poorly understood.  
In this thesis, I describe studies that set out to understand the signals that 
control astrocyte functions and properties, both in healthy brains and during 
dementia. First, I investigated how neurons communicate with astrocytes. I 
found that when neurons are more active, they changed levels of important 
genes in astrocytes. This in turn increased the ability of astrocytes to provide 
fuel to more active neurons – thus ensuring energy supply met energy demand 
in the healthy brain. Using mice kept in light versus darkness, and measuring 
the levels of astrocyte genes in the area of the brain receiving input from the 
eyes, I showed that the changes in astrocyte gene levels seen in response to 
active neurons also occurred in live animals.  
Next, I describe studies that set out to understand how astrocytes are affected 
during dementia. I used a mouse with a mutation associated with early-onset 
dementia in human patients and investigated how this changed levels of genes 
in astrocytes. I found that during dementia, astrocytes changed their properties 
in ways that are both harmful and protective to neurons. By boosting one of 
these key protective functions (the ability of astrocytes to clear damaging 
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molecules called “free-radicals”), I found that dementia-associated damage 
could be slowed down.  
Therefore, the studies in this thesis contribute towards our understanding of 
what controls astrocyte functions in health, and demonstrate that enhancing 





Astrocytes play a large number of roles essential for CNS health and are 
important mediators in CNS disease, demonstrating both neuroprotective and 
neurotoxic phenotypes.  Non-cell autonomous interactions between neurons 
and astrocytes have been implicated in regulating astrocyte function and 
phenotype, but the scope and mechanisms of how neuronal signals control 
astrocytes are poorly understood.   
The data presented in this thesis describe how neuron-astrocyte interactions 
influence astrocyte transcriptional pathways to control homeostatic and 
neuroprotective functions in health and disease. First, I show that healthy 
astrocytes are modulated by a physiological signal: neuronal synaptic activity. 
Using an in vitro astrocyte-neuron co-culture model, I describe how synaptic 
activity alters astrocyte transcription via CREB-dependent signalling to boost 
the astrocyte-neuron lactate shuttle pathway – an important pathway for energy 
provision in the CNS.  
Second, by exposing astrocyte-specific EGFP-ribosome reporter mice to a light-
stimulus paradigm, I demonstrate that altered synaptic activity influences 
astrocyte transcription in a more complex in vivo model. I further describe how 
activity-dependent neuronal and astrocyte transcriptional pathways are altered 
upwards or downwards when neuronal activity is suppressed during anaesthesia 
or when neuronal activity is enhanced with transcranial electrical stimulation. 
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Finally, I explore the consequences of neurodegenerative disease on astrocyte 
transcription and phenotype. Using a transgenic mouse model of 
frontotemporal dementia (FTD), I describe how neuronal tauopathy drives 
upregulation of both neurotoxic and neuroprotective astrocyte transcriptional 
signatures. One key signature found was upregulation of the cyto-protective 
transcription factor Nrf2 pathway, and I demonstrate that boosting Nrf2 in 
reactive astrocytes confers neuroprotection in our model of human tauopathy.  
Collectively, these investigations add to our growing understanding of how 
astrocyte transcription and function are altered both by physiological signals 
and during neurodegeneration, and highlight the astrocyte Nrf2 pathway as a 
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 Astrocyte functions during normal physiology 
Astrocytes are a common cell-type in the CNS (von Bartheld, Bahney and 
Herculano-Houzel, 2016). The concept that they provide mere passive 
structural support has become superseded by emerging research identifying a 
number of active astrocyte functions essential for CNS physiology in health and 
disease. Known astrocyte roles are outlined in Table 1-1.  
In this introduction, I expand upon specific astrocyte anatomical and functional 
adaptations of particular relevance to this thesis. I next discuss how these 
functions are modulated by intracellular and extracellular signals. Finally, I 
introduce how astrocyte function and phenotype change following injury and 





Table 1-1 Astrocyte Functions 
Category Function Description 
Neuronal health and  
synaptic transmission 
Synapse formation Release of prosynaptic molecules and function as part of the tripartite synapse (expanded 
below) 
Synapse elimination Mediate synapse elimination through MEGF10 and MERTK pathways (Chung et al., 2013). 
Neuronal growth Secretion of neurotrophic growth factors (BDNF, NGF, GDNF) (Houlgatte et al., 1989). 
Secretion of extracellular matrix 
(ECM). 
Express a range of proteoglycans essential for CNS extracellular matrix formation and 
neuronal adhesion molecules (N-cadherin, laminin and neural cell adhesion molecule 










K+ balance Elevated K+ following synaptic transmission is cleared by astrocytes; redistributed through 
astrocyte gap junctions and returned at sites of low K+ concentration via astrocyte Kir4.1 
channels (Hertz and Chen, 2016). 
Brain metabolism Produce lactate for neuronal metabolic function (expanded below).  
CNS glycogen storage Astrocytes are the predominant glycogen store in the CNS, and astrocyte glycogen is 
essential in protecting the brain from hypoglycaemia (Brown and Ransom, 2007). 
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Category Function Description 
CNS Physiology (Cont) 
Thyroid hormone activation 
Uptake inactive T4 hormone from the blood and convert to active T3 (Morte and Bernal, 
2014). Activated thyroid hormone is essential for myelination and brain development.  
 
Cholesterol synthesis 
Astrocytes have a key role in producing cholesterol. This is secreted and delivered to 
neurons as a complex with apolipoprotein (apo) E and required for neuronal membrane 
formation and synapse function (Mauch et al., 2001). 
 
Glymphatic flow 
Astrocyte pulsatile motion is coupled with water-egress through vascular-bound Aqp4 
channels required for pumping and clearing CNS waste through the glympathic system – 
the CNS equivalent of the lymphatic network (Iliff et al., 2012).  
 
Circadian rhythm 
Astrocyte regulation of extracellular glutamate modulates the oscillatory patterns of 
neurons in the suprachiasmic nucleus to regulate night-time activity of the mammalian 
circadian clock (Brancaccio et al., 2017).  
Neuroprotective functions Antioxidant function Provide antioxidant support to nearby neurons (expanded below).  
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Category Function Description 
Glutamate uptake Essential for CNS glutamate uptake and clearance (expanded below).  
Ammonia clearance 
Detoxify ammonia by converting it into glutamine and astrocyte dysfunction has been 
implicated in hepatic encephalopathy (Rao et al., 2005). 
Blood brain barrier and 
vasculature interactions 
CNS water homeostasis 
Express aquaporin water channels on their basal membrane which are essential for 




Astrocytes contact the vasculature, and hypothesised to be responsible for reactive 
hyperaemia – the process where blood flow in local parts of the brain is coupled to activity 
(expanded below).  
 
Regulation of blood brain 
barrier permeability 
Astrocyte end-feet are one constituent of the BBB, and astrocyte transporter expression 
and end-feet anatomy can modulate BBB permeability (expanded below).  
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Category Function Description 
Inflammatory Functions 
Formation of glial scar 
Following injury, astrocytes become reactive and proliferate, forming a glial scar to contain 
inflammatory processes. The neuroprotective vs neurotoxic effects of scar formation are 
described below.  
Inflammatory cytokine 
production and complement 
activation. 
Secrete both proinflammatory and antinflammatory cytokines and chemokines, including 
Il-1, IL-6, TNF-Alpha and and IFN-gamma (Lau and Yu, 2001). Secrete complement factors 
C1q and C3, which activates complement and postulated to mediate synapse loss in 




 Anatomical distribution and heterogeneity 
The anatomical distribution of astrocytes in the CNS is highly organised. They 
tile the entire CNS in a non-overlapping and contiguous manner. Their 
perivascular end-feet contact cerebral blood vessels directly (Mathiisen et al., 
2010), and they extend peripheral processes to make contact with neurons at 
synapses, dendrites, axons and somata (Weber and Barros, 2015). Thus they act 
as the interface between neurons and the cerebral vasculature (Figure 1.1).   
Soon after their discovery by Rudolf Virchow (Virchow, 1858), it became clear 
that astrocytes represent a heterogeneous population. For over a hundred years 
they have been classified as two main subtypes based on morphology and 
location: grey matter (protoplasmic) astrocytes and white matter (fibrous) 
astrocytes (Cajal, 1909; Miller and Raff, 1984). In addition, it is also recognised 
that that there are specialized astroglia, such as Bergmann glia in the cerebellum 
or Müller cells of the retina (Farmer and Murai, 2017).  
With the advent of transcriptomics, it is emerging that astrocytes demonstrate 
even greater diversity. Recent studies have described regional (Itoh et al., 2018) 
and cortical layer-specific (Bayraktar et al., 2018; Lanjakornsiripan et al., 2018) 
heterogeneity in astrocyte populations. Additionally, astrocytes demonstrate 
heterogeneity in their phenotypic response to injury or disease. This is discussed 




Figure 1.1 - Cytoarchitectural relationship of astrocytes within the 
neuro-glia-vascular unit (from Demetrius, Magistretti and Pellerin, 
2015). Astrocytes tile the vasculature and communicate with neuronal 
bodies and synapses, acting as an interface between the blood stream 
and the nervous system.  
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  Astrocyte roles in CNS signalling 
 Synapse modulation 
 
Astrocytes play important roles in synapse formation and maintenance, both 
during CNS development and in adulthood. The importance of astrocytes in 
promoting synaptogenesis was first demonstrated by the observation that 
rodent neurons cultured in isolation have very few synapses. The addition of 
astrocytes leads to an increase in both synapse number and strength (Pfrieger 
and Barres, 1997). An individual astrocyte covers an area that contains (and 
hence could make contact with) as many as 105 synapses in the mouse cortex 
(Bushong et al., 2002). Their close proximity with the pre-synaptic and post-
synaptic clefts has led to the development of the “Tripartite” synapse hypothesis 
(Figure 1.2). This postulates that astrocytes play a critical role in influencing 
and shaping synapse formation and strength (Allen and Eroglu, 2017).  
Astrocytes strengthen synapses through multiple contact and secreted signals.  
Key astrocyte factors identified to enhance synapse number and transmission 
include thrombospondins (Christopherson et al., 2005); secreted protein acidic 
and rich in cysteine-like 1 (SPARCL1) (Kucukdereli et al., 2011); glypicans 4 and 
6 (Allen et al., 2012); cholesterols (Mauch et al., 2001); and cytokines including 
TNF-α and TGF-β (Diniz et al., 2012).  
Astrocyte ensheathment of synapses has been shown to be a dynamic process 
influenced by numerous factors, including neuronal activity (Bernardinelli et al., 
2014), and glia have been shown to regulate the formation of multiple synapse 
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types, including cholinergic, GABAergic and glumatergic synapses (Cao and Ko, 
2007, Elmariah et al., 2005, Ullian et al., 2001). 
 
 
Figure 1.2 - The tripartite synapse (adapted from Allen and Barres, 
2009). Astrocytes ensheath synapses and are hypothesised to respond 
to neuronal signals and to secrete factors that modulate synapse 




As well as positive roles in promoting synapse formation, astrocytes have been 
implicated in synapse elimination. This is both via direct means (e.g. 
phagocytosis) (Chung et al., 2013) and by indirect means involving microglia 
and complement activation (Bialas and Stevens, 2013). Synapse elimination is 
an important process involved in both normal physiology for circuit remodelling 




Astrocytes have been postulated to release gliotransmitters: neuroactive 
substances that have been implicated in modulating synaptic activity. This is 
discussed in further detail in section 1.2, together with mechanisms by which 
neurons may direct astrocyte signalling.  
 
 Functions for CNS homeostasis:  
 Glutamate uptake 
 
Glutamate is the main excitatory neurotransmitter in the CNS. It acts primarily 
on N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA) receptors, and has important roles in learning, 
memory and motor function. However, excess glutamate can lead to 
excitotoxicity and neuronal death (Dong, Wang and Qin, 2009).   
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Astrocytes are the main uptakers of glutamate in the CNS (Anderson and 
Swanson, 2000). They express high-affinity glutamate transporters (EEAT1 and 
EEAT2) which are coupled to transmembrane sodium flux. High expression of 
glutamine synthetase inside the astrocyte converts glutamate into glutamine. 
This maintains a gradient for continued glutamate uptake, with glutamine being 
recycled back to neurons for reconversion into glutamate. This glutamate-
glutamine cycle is essential for maintaining normal synaptic function, and 
critical following injury in removing excess glutamate from the CNS.  
 Neurovascular coupling 
 
As described above, astrocyte end-feet line the vasculature and along with 
endothelium and pericytes, constitute the blood brain barrier. The blood brain 
barrier is characterised by a specialised network of tight-junctions which limits 
movement of hydrophilic substances between the bloodstream and the CNS 
(Cabezas et al., 2014). This both protects the brain from toxic substances and 
allows tight control of the CNS physiological environment. Astrocytes express a 
large number of specialised transporters (for example, the glucose transporter 
GLUT1 and aquaporins) which actively transfer substances across the BBB to 
regulate metabolic homeostasis and water balance in the CNS (Nagelhus and 
Ottersen, 2013).   
Astrocytes may regulate blood flow into the CNS and acts as an important cell-
type in determining the phenomenon of reactive hyperaemia (Nippert, 
Biesecker and Newman, 2018). Reactive hyperaemia is the process by which 
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blood supply to the brain is coupled to energy demand. Increased neuronal 
activity leads to localised vasodilation of regulating arterioles and capillaries, 
increasing local blood flow. The effects of astrocyte stimulation on blood-vessel 
dynamics is complex and incompletely understood. Experiments have shown 
that calcium transients in astrocytes can induce both vasodilation and 
vasoconstriction (Mulligan and MacVicar, 2004), with differing signalling 
pathways postulated to act between capillaries and arterioles (Mishra et al., 
2016). Signalling messengers that have been implicated include glutamate 
induced release of astrocyte vasoactive substances such as nitric oxide, 
arachidonic acid, prostaglandins and 20-hydroxyeicosatetraenoic acid (20-
HETE) which have both direct and indirect effects on vascular smooth-muscle 
(Howarth, 2014). Astrocyte-endothelial interactions are also important for 




Astrocytes have been implicated in playing a key role in CNS metabolic 
homeostasis. The CNS has high energy requirements. Whilst comprising only 
2% of total body mass, the brain utilises approximately 20% of total oxygen and 
25% of total glucose consumed by the body (Bélanger, Allaman and Magistretti, 
2011). Most of this energy fuels synaptic activity rather than action potentials 
and energy requirements can increase significantly due to excitotoxicity during 
times of injury and disease (Attwell and Laughlin, 2001).  
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Whilst sources of energy provision for neurons were classically considered to be 
from oxidation of glucose or ketone bodies taken up directly by neurons, the 
astrocyte-neuron lactate shuttle (ANLS) hypothesis (Magistretti et al., 1999; 
Bélanger, Allaman and Magistretti, 2011) postulates that that astrocyte-derived 
metabolic precursors (lactate and pyruvate) may serve as the predominant fuel 
source for neuronal oxidative phosphorylation (Figure 1.3). 
 
Figure 1.3 - The Astrocyte-Neurone Lactate Shuttle (adapted from 
Bélanger, Allaman and Magistretti, 2011).  Astrocytes take up glucose 
from the bloodstream for conversion into lactate via glycolysis. Lactate 
is then exported to neurons where it is utilised to generate ATP via the 
citric-acid cycle and oxidative phosphorylation. Lactate production is 
hypothesised to be acutely coupled to glutamate uptake. Changes in 
Na/K+ gradients across the astrocytes due to glutamate uptake require 
increased ATP to power membrane Na/K pumps. ATP production is 
provided by increased glycolytic flux, which generates lactate for 
export to neighbouring neurons.  
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Astrocytes are suited morphologically and phenotypically to the role of 
providing CNS metabolic support. Their anatomical position adjacent to, and 
wrapped around, the cerebral vasculature allows uptake of metabolic substances 
directly from the bloodstream. High concentrations of the high capacity glucose 
transporter GLUT1 on their endfeet act as the predominant route for glucose 
entry into the CNS (Chuquet et al., 2010; Zimmer et al., 2017).  
Astrocytes also have several biochemical adaptations for high glycolytic rates 
and lactate export. Pyruvate dehydrogenase (an essential enzyme for allowing 
entry of pyruvate into the Krebs cycle) is kept at reduced levels in astrocytes by 
phosphorylation (Itoh et al., 2003), and astrocytes have low levels of the 
aspartate-glutamate complex aralar (Ramos et al., 2003).  This means that 
conversion of pyruvate to lactate is the preferred pathway for regenerating NAD 
cofactor in astrocytes, hence promoting this pathway and lactate formation. 
Finally, astrocytes have high levels of the enzyme 6-phosphofructose-2-kinase-
fructose-2,6- bisphosphatase-3 (Pfkfb3), a key activator of 
phosphofructokinase, the rate-limiting step of glycolysis. Pfkfb3 is continuously 
degraded in neurons and therefore levels are virtually absent – resulting in a 
lower glycolytic rate in neurons (Herrero-Mendez et al., 2009).  
The importance of the ANLS in CNS function is illustrated by gene-interference 
experiments in drosophila, where silencing of glial glucose transporters or glial 
glycolysis genes cause neuronal death, whilst silencing of neuronal glycolytic 
genes result in no abnormal phenotype (Volkenhoff et al., 2015). Inhibition of 
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astrocyte-specific lactate exporters lead to memory impairment and loss of LTP 
in rodents, which is rescued by lactate infusion but not by glucose (Suzuki et al., 
2011).  In this study, inhibition of neuronal lactate importers also leads to 
memory impairment but this cannot be rescued by lactate, suggesting the 
requirement for lactate transfer from astrocytes to neurons. And lactate has 
been suggested to have other neurotrophic and memory-promoting effects 
independent of its role as an energy substrate, for example by signalling through 
hydroxycarboxylic acid (HCA) receptors (DiNuzzo, 2016).  
Therefore, the above studies demonstrate that the ANLS is an important 
pathway for neuronal and CNS homeostatic function. However, the manner in 
which this pathway is regulated, and specifically the manner in which neuronal 
activity influences astrocyte capacity to provide metabolic CNS support was 




 Neuroprotective functions:  
In addition to roles in normal physiology, astrocytes have a number of 
important neuroprotective roles.  
 
 Antioxidant protection 
 
Neurons are especially vulnerable to oxidative stress (Dringen, Gutterer and 
Hirrlinger, 2000). Their high metabolic requirements result in the generation of 
high levels of reactive oxygen species (ROS). This is coupled with an increased 
vulnerability to oxidative damage given their poor regenerative potential and 
requirement to function for an entire lifetime. Therefore the CNS requires 
significant and robust antioxidant pathways.  
Paradoxically, neurons have low intrinsic antioxidant capacity, exhibiting low 
levels of key antioxidant molecules such as glutathione peroxidase, catalase and 
superoxide dismutases (Bell and Giles E Hardingham, 2011).   This is achieved 
by epigenetic suppression of the antioxidant master transcription factor NF-E2-
related factor 2 (Nrf2) in neurons and is believed to be due to the essential 
requirement for redox signalling for neuronal development (Bell et al., 2015). 
Therefore, neurons rely on neighbouring astrocytes, which express high levels 
of Nrf2, for antioxidant protection. Nrf2 activation in astrocytes leads to an 
enhanced capacity for astrocytes for generating glutathione precursors (e.g. 
cysteinylglycine), which can be transported to neurons and used to generate 
glutathione (a key antioxidant) in an activity-dependent manner.  
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Figure 1.4 - The transcription factor Nrf2 is activated in response to 
antioxidant stress in astrocytes. A. (Adapted from: Houghton, Fassett and 
Coombes, 2016). An altered cellular redox environment leads to oxidation 
of a critical cysteine residue on the Nrf2 inhibitor KEAP-1 causing its 
dissociation from Nrf2. This allows Nrf2 translocation into the nucleus, 
where it activates a battery of antioxidant genes. B. (Adapted from 
Fernandez-Fernandez et al., 2012.) Nrf2 activation in astrocytes leads to the 
synthesis of glutathione precursors which are supplied to neurons to 
provide antioxidant support.  
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The levels of key antioxidant pathways are dynamically regulated within the cell 
to ensure that antioxidant capacity matches changing levels in ROS production. 
Nrf2 nuclear levels are kept low by being bound to its negative regulator Kelch-
like erythroid cell-derived protein with cap ‘n’ collar homology associated 
protein 1 (Keap1) (Kansanen et al., 2013) (Figure 1.4).  This association targets 
Nrf2 ubiquitination for proteosomal degradation. Changes in the cellular redox 
environment leads to modification of the cysteine residues on Keap1. This leads 
to dissociation of Keap1 from Nrf2, allowing its translocation in the nucleus. 
Here it binds to antioxidant response elements (ARE) leading to the activation 
of a large number of antioxidant genes as summarised in Table 2.   
Evidence for the importance of astrocytic vs neuronal Nrf2 can be demonstrated 
by knock-out experiments. Nrf2-deficient neurons do not demonstrate 
increased vulnerability, and pharmacological activation of Nrf2 in neurons does 
not increase levels of Nrf2 target genes. However activation of Nrf2-mediated 
transcription in astrocytes is able to confer neuroprotection via a mechanism 





Astrocytes play an expanding number of roles essential for CNS homeostasis 
and neuroprotection. In this thesis, I aim to investigate how specific signals 
can regulate these functions to alter CNS homeostatic pathways and examine 




Table 1-2 Nrf2 target genes and key antioxidant pathways in the CNS 
Nrf2 Target Gene(s)  Function 
Haemoxygenase (Hmox-1) 
Generates the antioxidants carbon monoxide and bilirubin 
from haemoglobin. 
Superoxide dismutases (Sod) 
Converts superoxide (O2-) into molecular oxygen or hydrogen 
peroxide (H2O2), for subsequent breakdown by catalase.  
Catalase (Cat) Catalyses the conversion of H2O2 into water and oxygen. 
Glutathione pathway 
 enzymes. 
Upregulation of genes needed for the production, use and 
recycling of glutathione, including glutatmylcysteine ligase 
(Gclc), glutathione reductase, glutathione-s-transferase(GST) 
and glutathione synthetase.  Glutathione reduces peroxides 
and ROS directly or by acting as an electron donor for 
glutathione peroxidases.  
NAD(P)H: quinone acceptor 
oxidoreductase (NQO1)  
Couples NADPH to oxidise free-radical quinones into 
hydroxyquinones.  
Thioredoxin (Trx),  
sulfiredoxins (Srxn) and 
Peroxiredoxin (Prx)  
pathway enzymes 
 
A family of proteins that remove peroxides. Trx donates 
electrons to oxidised proteins such as Prx, reducing their 
disulfide bonds. This allows Prx to remove H2O2. Following a 
severe oxidative insult, the cysteine residues on Prx can be 
oxidised to sulfinic or sulfonic acid. These cysteines can be 
reduced by Srxn (ATP-dependent reductases), hence 




 Signals that control astrocyte function and phenotype 
Given the large number of important astrocyte functions outlined above, 
emerging data that astrocytes are controlled by a number of internal and 
external signals is not surprising. Whilst a complete description of all signalling 
pathways implicated to influence astrocytes is beyond the scope of this 
introduction, in this section I will expand further on specific key signalling 
pathways and those of relevance to the studies described in this thesis.  
 
 Intracellular signals 
 
 Astrocyte calcium signalling  
 
The principle intracellular signalling molecule that has been studied in 
astrocytes is calcium. The observation that extracellular glutamate leads to 
intracellular calcium fluctuations in astrocytes was the first indication that 
astrocytes could dynamically respond to their extracellular environment and 
were more than passive support cells in the CNS (Cornell-Bell et al., 1990).   
Astrocytes demonstrate a complex pattern of calcium fluctuations, both at rest 
and in response to neuronal activity. Calcium fluctuations can be restricted to 
microdomains (called calcium ‘sparkles’ or ‘bursts’) or propagate throughout the 
cell as calcium waves (Khakh and McCarthy, 2015; Bindocci et al., 2017). 
Astrocytes are connected to each other via gap junctions, allowing calcium wave 
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propagation to neighbouring non-stimulated astrocytes. It has been suggested 
that astrocyte calcium waves can be integrated, processed and transmitted – 
forming a secondary CNS communications network augmenting neuronal 
networks in the CNS (Scemes and Giaume, 2006). However, the exact 
consequences and implications of astrocyte calcium activity on astrocyte 
function has not yet been fully understood.  
The upstream activators and downstream effectors of astrocyte calcium signals 






Figure 1.5 - Upstream and downstream pathways involved in 
astrocyte calcium signalling (Adapted from Slusarski and Pelegri, 
2007). (1) Binding of agonists induces activation of g-protein coupled 
receptors (GPCR) and receptor tyrosine kinases (RTK). (2) Activation 
of phospholipase C leads to hydrolysis of PIP2 giving rise to IP3 and 
DAG. (3) IP3 binds to receptors on the ER and triggers Ca2+ release 
from intracellular stores. (4) Signalling can cascade by calcium-
induced calcium release with Ca2+ binding to ryanodine receptors 
(RyR).  (5) Intracellular Ca2+ activates Ca2+ binding proteins (6) 
Alternative pathways activates other kinases (e.g. PKC). (7) Signalling 
is controlled by Ca2+ extrusion via plasmalemmal pumps and 
Na+/Ca2+ exchange as well as by uptake into intracellular stores, 
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 G-protein coupled receptors 
 
Signal transduction in neurons typically occurs via ionotropic receptors such as 
the NMDA and AMPA channels. These alter cellular current and ion flow 
through the cell membrane, leading to activation of voltage-dependent 
channels and inducing signal propagation via action-potentials.  Astrocytes do 
not typically express voltage-dependent channels and are considered to be 
electrically unexcitable. Instead they utilise a number of metabotropic receptors 
for cellular signalling (Bradley and Challiss, 2012), which respond to signalling 
substances including glutamate (acting via mGlu3 and mGlu5 receptors), 
noradrenaline, VIP, adenosine and ATP (Bradley and Challiss, 2012; Orr et al., 
2015). 
These ligands bind to G-protein receptors (GPRs) which in turn drive a number 
of downstream signalling pathways.  GPRs can be categorised into Gq, Gs and 
Gi subtypes. Gq receptors couple to protein kinase C (PKC) to induce activation 
of phospholipase C, leading to the production of inositol 1,4,5-trisphosphate 
(IP3). This binds specific receptors in the endoplasmic reticulum causing Ca2+ 
release.  This calcium release then propagates throughout the cell and is 
modulated by both positive and negative control mechanisms. Gs and Gi 
receptors couple to adenylate-cylase (either activating or inhibiting the enzyme) 
leading to increased production of the second messenger cAMP, and activation 
of protein-kinase A.  This can then phosphorylate and activate transcription 
factors as detailed below.  
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 Role of the CREB transcription factor in astrocytes 
 
Initiation of the above second messenger cascades ultimately leads to 
downstream activation of numerous transcription factors. The full discussion of 
all astrocyte transcription factors is beyond the scope of this introduction, but I 
will consider the role of one key CNS transcription factor here - c-AMP 
responsive element binding protein (CREB).  
CREB is part of a family of transcription factors, termed the basic leucine zipper 
domain family, which includes other similar factors such as Activating 
Transcription Factor 1 (ATF1) and cAMP Responsive Element Modulator 
(CREM) (Lonze and Ginty, 2002). CREB family transcription factors can be 
activated by multiple pathways. Classical CREB activation occurs via G-coupled 
receptors that induce cAMP- PKA signalling, allow the nuclear localisation of 
PKA and phosphorylation of CREB at Ser 133 (Shaywitz and Greenberg, 1999). 
CREB can also be activated by Ca2+, both by PKC signalling and by activation of 
calmodulin dependent kinases (CamKs), as well as through growth factor 
signalling pathways (Figure 1.6).  
These pathways converge to induce phosphorylation of CREB which allows it to 
dimerise and bind to DNA at cAMP regulatory element (CRE) regulatory sites. 
CRE is classically described as an 8 nucleotide palindromic sequence 
(TGACGTCA), but this has been expanded by later works to include sequence 
variations (Craig et al. 2001). Binding of CREB to CRE sites induces the 
expression of a large number of genes that modulate cellular function. 
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Further complexity of control arises from CREB exhibiting multiple splice 
variants which demonstrate different properties. Some of these variants (for 
example one isoform produced by an alternative intronic promoter, inducible 
cAMP response element repressor (ICER)), act as a transcriptional repressor 





Figure 1.6 - Activation of the CREB transcription factor via 
upstream signalling (Adapted from Wang et al., 2018).The classical 
pathway of CREB activation follows G-protein coupled receptor (GPCR) 
activation. This binds and activates adenylate cyclase (AC), which 
produces cAMP. This activates phosphokinase A (PKA). PKA enters the 
nucleus and phosphorylate CREB at Ser133, which causes its activation. 
Alterative pathways include growth factor activation of receptor 
tyrosine kinases (RTK) acting via Ras/Raf/MEK/ ERK/p90/RSK 
pathways, which can induce phosphorylation of CREB at alternative 
sites. Finally, in excitable cells, activation of excitatory NMDA receptors 
increases intracellular calcium, and induces CREB phosphorylation 
through Ca2+/CaMK-dependent pathways. 
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The consequence of CREB activation in neurons has been well studied. 
Induction of CREB target genes are essential for neuronal development and 
promote changes in synaptic plasticity, learning and memory (Lonze and Ginty, 
2002). In addition, CREB activation induces pro-survival gene expression and 
promotes neuronal resilience to injury.  
The role of CREB in astrocytes is less well understood. Recent publications have 
identified that activation of CREB drives distinct transcriptional programmes in 
astrocytes compared to those in neurons (Pardo et al., 2017) and enhancing  
CREB activation in astrocytes can reduce neuronal damage following focal 
cortical injury (Pardo et al., 2016).  
 
 Extracellular signals. 
 
Astrocytes receive a number of extracellular signals from other CNS cell-types 
that have been demonstrated to alter their transcription and phenotype. 
 
 Neuronal contact  
 
Astrocytes in vivo differ markedly both morphologically and in their 
transcriptome from those cultured alone in vitro (Cahoy et al., 2008 ). 
Specifically, in vitro astrocytes demonstrate both immature characteristics as 
well as some features consistent with a reactive phenotype  
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Recent work has expanded our understanding of how neurons, through direct 
contact with astrocytes, induce changes in function and phenotype.  Co-
culturing astrocytes with neurons induces the distinctive stellate shape seen in 
vivo, which is mediated through astrocytic neuroligan signalling (Stogsdill et al., 
2017). Co-culture with neurons also drives transcriptional changes in astrocytes 
towards those of a more in vivo signature, and induced functional maturity as 
measured by glutamate uptake capacity, with transcriptional and functional 




 Synaptic activity - consequences on neuronal transcription  
 
One of the most important and defining features of CNS communication is 
synaptic activity. Action potentials transmitted down neuronal axons induce the 
release of neurotransmitter substances at the synapse. Besides allowing 
communication and propagation of signals between neurons, synaptic activity 
has a profound effect on neuronal health and function by mediating changes in 
neuronal transcription – so called “synapse-to-nucleus” signalling (Greenberg, 
Ziff and Greene, 1986; Flavell and Greenberg, 2008). Transcriptional changes 
induced by synaptic activity promotes axonal and dendritic outgrowth, bringing 
together pre- and postsynaptic aspects of neuronal circuitry (Henley and Poo, 
2004).  Calcium-induced changes to neuronal transcription programmes also 
promote synapse maturation (Redmond and Ghosh, 2005).  
In addition to effects on neuronal function, synaptic activity also promotes 
transcriptional changes that promote neuronal survival, conferring resistance to 
both excitotoxic and apoptotic insults. Synaptic activity, via activation of 
NMDAR-mediated Ca2+-dependent transcription factors such as NFAT, NFI-A 
and CREB in neurons, leads to the expression of a family of genes called activity-
regulated inhibitors of death (AIDs) (Hardingham and Bading, 2003). These 
genes confer resistance to neuronal death by a number of mechanisms, 
including increasing mitochondrial resistance to stress.  Neuronal activity also 
promotes the expression of a number of neurotrophic factors (for example Bdnf, 
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Fgf2). Synaptic activity has been demonstrated (by suppressing key pro-
apoptotic transcription factors such as p53 and forkhead box protein O (FOXO) 
to suppress components of both intrinsic and extrinsic apoptosis pathways, 
further promoting neuronal resilience to injury and disease (Léveillé et al., 
2010).   
Finally, synaptic activity enhances neuronal resilience and health by boosting 
neuronal antioxidant defences (Baxter et al., 2015, Baxter and Hardingham, 
2016). Whilst neurons suppress Nrf2 and rely on astrocyte antioxidant 
pathways for the supply of glutathione precursors, synaptic activity is able to 
regulate mechanisms to utilise these precursors, as well as control other 
intrinsic Nrf2-independent antioxidant systems. Synaptic activity regulates 
both GSH pathway genes and other antioxidant genes that form part of the 
thioredoxin-peridoxin pathways such as Gclc, Gsr, Srxn1 and xCT. Whilst some 
of these genes are Nrf2 dependent, neuronal activity regulates these genes in an 
Nrf2-independent manner by means of utilising other activity-dependent 
transcription factors such as AP-1 and ATF4 (Deighton et al., 2014).  
 
 Synaptic activity – consequences on astrocyte transcription 
 
Given that synaptic activity has such profound consequences on neuronal 
transcription as described above, a natural question is whether it influences 
astrocyte transcription to alter astrocyte function.   
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Astrocytes have been shown to respond to neurotransmitters such as, for 
example, glutamate the main excitatory neurotransmitter in the CNS.  As 
discussed above, single synaptic activation of neighbouring neurons can lead to 
altered astrocytic Ca2+ responses. Unlike the neuronal response to glutamate, 
which mainly involves ionotrophic glutamate receptors such as NMDA or 
AMPA, the astrocyte response typically involves metabotropic glutamate 
receptors (mGluRs) (Panatier et al., 2011).  
Human studies on mature astrocytes extracted via immunopanning from 
human brain tissue suggest that mature human astrocytes responded to 
glutamate administered in the medium, and this was inhibited by mGluR5 
antagonists (Zhang et al., 2016). Other receptors including adrenergic, 
purinergic, serotonin and muscarinic receptors have also been described on 
astrocytes (Porter and McCarthy, 1997) and astrocytes have been shown to 
respond to other neurotransmitter substances such as vasoactive peptide, ATP 
and noradrenaline which act via GPCRs as outlined above.  
Exposure to glutamate has been shown to alter astrocyte glutamate transporter 
levels (Yang et al., 2009) and transporter position (Murphy-Royal et al., 2015). 
Glutamate also affects key astrocyte metabolic processes including aerobic 
glycolysis (Pellerin and Magistretti, 1994a), mitochondrial positioning (Jackson 
et al., 2014), and the response to hypoxia (Vanzulli and Butt, 2015).  
Neuronal activity has also been suggested to increase astrocyte Nrf2 expression. 
Coculture of astrocytes and neurons utilising membrane-inserts physically 
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separating the cell-types but allowing diffusion of soluble messengers, 
combined with elevated neuronal activity in intact brain slices, neuronal activity 
was found to increase levels of astrocytic Nrf2 (Habas et al., 2013).  This 
required a well-developed synaptic network, action potential firing and was 
reduced by glutamate receptor inhibitors (NMDA and mGluRs) and 
intracellular Ca2+ chelation. 
Finally, more recent published work from the Hardingham lab (including data 
from this thesis) describes the effect that that neuronal activity in vitro had 
profound influence on astrocyte transcription and function (Hasel et al., 2017). 
And a recent study using single-cell sequencing of visual cortices from mice 
exposed to 1h and 4h light stimulus also revealed the capacity of neuronal 
activity to change astrocyte transcription (Hrvatin et al., 2018). These studies 




Given the close proximity to synapses, and the response to neurotransmitter 
substances, astrocytes have also been implicated to release neuroactive 
substances in response to synaptic signalling. These substances are 
hypothesised to signal back to neurons and modulate synaptic transmission. 
Postulated gliotransmitters include amino acids  such as glutamate and D-serine 
(Parpura et al., 1994; Schell, Molliver and Snyder, 1995); nucleotides such as 
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ATP (Bal-Price, Moneer and Brown, 2002) and complex peptides such as ANP 
and BDNF (Krz̄an et al., 2018).  
The concept of gliotransmission is controversial. Positive evidence supporting 
gliotransmission include the blockage of long-term potentiation (LTP) in the 
hippocampus by Ca2+ chelation in astrocytes (Henneberger et al., 2010), and the 
induction of neuronal activity in nearby neurons by stimulating astrocytes – a 
phenomenon that can be transmitted through neighbouring astrocyte gap 
junctions (Nedergaard, 1994). In vivo evidence that supports glia transmission 
includes the reduction of cortical gamma oscillations and behavioural deficits 
induced by astrocyte-specific inhibition of vesicle release by tetanus toxin (Lee 
et al., 2014).  
Negative evidence against gliotransmission includes the lack of neuronal or 
behaviour changes seen in transgenic mouse lines that both activated astrocyte 
calcium signalling via a synthetic GPR or inhibited calcium signalling via 
blockade of the IP3 pathway (Agulhon, Fiacco and McCarthy, 2010).  And 
astrocytes from specific brain regions in vivo appear to have very low levels of 
RNA and protein expression of the Ca2+-sensitive vesicular release machinery 
for the commonly described gliotransmitters (Chai et al., 2017).  
Therefore, whilst astrocytes are closely involved in synapses, and have been 
implicated to be both modulated by synaptic activity, and in turn to modulate 
neurotransmission, the exact role of neuron-astrocyte interactions in normal 
physiology and in disease remains incompletely understood.  
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 Interactions with other CNS cell-types.  
 
Whilst a full discussion is beyond the scope of this introduction, it is important 
to note that astrocytes also have important interactions with other CNS cell-
types. These include microglia, oligodendrocytes, pericytes and endothelial 
cells.  
Astrocyte-oligodendrocyte interactions have been suggested to have a key role 
in promoting remyelination following injury by supplying cholesterol 
precursors needed for myelin formation (Itoh et al., 2018). And astrocytes 
interact with pericytes and endothelium cells to regulate blood-brain barrier 
properties as described above. Finally, there is a growing body of evidence that 
microglia-astrocyte crosstalk is essential in regulating astrocytosis and in 
determining the fate of reactive astrocytes in response to CNS injury. A fuller 
description of how microglia may influence astrocyte phenotype in disease is 
detailed in section 1.3.1.  
Section Summary 
Astrocytes alter intracellular signalling pathways in response to extracellular 
signals, especially from other CNS cell-types such as neurons. However, the 
full consequence of these signals on astrocyte transcription and function are 
poorly understood. In this thesis, I describe studies aimed at better 
understanding the astrocyte response to neuronal signals and the consequence 
on key homeostatic and metabolic functions. 
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 Astrocytes during disease. 
 Reactive astrocytes 
The previous sections have described the important roles that astrocytes play 
during normal physiology. Since astrocytes were first described, it has been 
observed that they alter their characteristics in response to disease and injury: a 
term called reactive astrocytosis (Virchow, 1855; Liddelow and Barres, 2017).  
Morphologically, reactive astrocytes hypertrophy, reduce their stellate 
appearance, and following some insults undergo proliferation to form a glial 
scar. Functionally, they demonstrate altered intracellular calcium signalling; 
reduced glutamate uptake capacity; production of extracellular matrix 
molecules; and the secretion of inflammatory mediators such as Il-6, TGF-B and 
TNF-alpha (Liddelow and Barres, 2017). Reactivity is a heterogeneous response, 
encompassing a spectrum of morphological, transcriptional and functional 
changes. The nature and duration of reactivity is determined by the nature and 
strength of injury or insult.  
It is emerging that reactive astrocytes can demonstrate both neuroprotective 
and neurotoxic roles. Reactive astrocytes in spinal cord injury have been 
demonstrated to secrete inhibitory extracellular matrix molecules that inhibit 
neurite outgrowth and lead to regeneration failure (Yiu and He, 2006). 
Conversely, reactive astrocytes have also been shown to have beneficial effects. 
In spinal cord recovery, removal or inhibition of astrocyte scar formation 
 38 
resulted in reduced spontaneous regrowth of transected axons following cord 
injury (Anderson et al., 2016).  
More detailed profiling of reactive astrocytes has become possible recently with 
RNA-sequencing. This has revealed distinct transcriptional signatures 
associated in response to different injury paradigms (Zamanian et al., 2012). 
This study described distinct types of reactive astrocytes produced in response 
to an inflammatory insult (LPS injection) vs an ischaemic insult (middle 
cerebral artery occlusion). These two reactive astrocyte types were termed “A1” 
vs “A2” to reflect the “M1” vs “M2” nomenclature that has previously been 
utilised to describe macrophage and microglial responses.   
A1 astrocytes, produced in response to inflammation, upregulate many genes 
that are neurotoxic (for example, genes associated with activation of the 
complement cascade) and were demonstrated to be detrimental to neuronal 
health and synapses. They had reduced ability to induce synapse formation and 
secreted an unidentified toxin that specifically induced neuronal and 
oligodendrocyte apoptosis (Liddelow et al., 2017).  
In contrast, A2 astrocytes, produced in response to ischaemic injury,  
upregulated many neuroprotective genes that are involved in the astrocyte 
antioxidant response and promoting synapse repair, and have been 
demonstrated to be broadly neuroprotective (Hayakawa et al., 2014).  
Whilst this simple binary classification of reactive astrocytosis (A1 – neurotoxic 
vs A2 - neuroprotective) is most likely an oversimplification of a complex and 
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heterogenous response to injury, it nevertheless serves as a useful framework to 
describe the manner in which astrocytes can have both neurotoxic and 
neuroprotective roles in the context of injury.  
Whilst the signals that modulate astrocyte phenotype are incompletely 
understood, non-cell autonomous interactions between astrocytes and other 
CNS cells are believed to be important.  Recently it has demonstrated that 
inflammatory processes that act to push astrocytes towards an A1 phenotype 
requires signalling via activated microglia through the release of specific 
cytokines (IL1a, TNFa and C1a) which modulated astrocyte phenotype into an 
A1 vs A2 profile (Liddelow et al., 2017).  
The full extent of the signals that control astrocyte phenotype, as well as a more 
complete understanding of what happens to astrocyte phenotype in a more 
chronic and complex neurodegenerative process such as dementia are not 
understood, and developing a better understanding of these questions forms a 
key aim of this thesis.  
 
 Astrocytes and dementia  
Astrocytes have been implicated as playing important roles as both upstream 
mediators and downstream effectors in several neurodegenerative diseases. 
These include: dementias such as Alzheimer’s (AD) (Cai et al., 2012), 
frontotemporal dementia (FTD) (Radford et al., 2015), Parkinson’s disease 
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(Rappold and Tieu, 2010); Huntingtons disease (Tong et al., 2014); and 
amyotrophic lateral sclerosis (ALS) (Nagai et al., 2007; Serio et al., 2013).  
In this thesis I describe studies investigating how astrocytes respond to 
neurodegeneration in a transgenic model of human tauopathy and FTD. 
Therefore, I will now expand upon the general pathology involved in dementia 
(AD and FTD) and the current understanding of the role that astrocytes may 
play in these diseases.   
 
 Dementia – definition and pathology 
 
The term dementia encompasses a range of different neurodegenerative 
conditions that lead to a progressive decline in memory, cognitive function and 
behavioural changes. The two most common causes of dementia are 
Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Dementia 
remains a massive global clinical and economic problem. It affects 48.4 million 
individuals worldwide and the lifetime risk of developing dementia in the 
western world is estimated to be as large as 25.9% for women, and 13.7% for 
men (Licher et al., 2018), with the global cost of dementia estimated to rise to 
approximately $1 trillion annually by 2018 (World Alzheimer’s Report, 2015). 
Aetiologically, these diseases are associated with ageing, as well as 
environmental and genetic risk-factors. 
Histopathologically, dementias are characterised by the presence of intra and 
extracellular aggregates of misfolded proteins (Lippens et al., 2007). These 
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include β-amyloid and hyper-phosphorylated tau protein in Alzheimer’s 
disease, and hyper-phosphorylated tau and transactivation-response-element 
DNA-binding protein 43 (TDP-43) aggregates in FTD.  Accumulation of 
misfolded protein is thought to initiate a cascade resulting in inflammation, 
synaptic loss, mitochondrial dysfunction and loss of antioxidant homeostasis 
(De Strooper and Karran, 2016), ultimately resulting in neuronal death.  
β-amyloid is a 33-43 kDa peptide that constitutes the extra-cellular amyloid 
plaques found in AD. β-amyloid is derived from cellular amyloid precursor 
protein (APP), which is processed by cellular secretases to yield soluble amyloid 
monomers (O’Brien and Wong, 2011) . According to the amyloid cascade 
hypothesis, oligomerisation of amyloid protein yields toxic soluble oligomers 
and toxic non-soluble fibrils and plaques (Reitz, 2012).   
Tau is a 55-74 kDA microtubule associated protein (Pîrşcoveanu et al., 2017). 
In health, tau binds reversibly to the cellular microtubules and regulates 
cytoskeletal function and transport. Alternative splicing can generate multiple 
isoforms of the protein. Isoforms have different affinities for microtubule 
binding and abnormalities in ratios of tau isoforms have been implicated in 
disease. Post-translational modifications of tau, and in particular its 
phosphorylation state, are key modifiers of its function. Hyperphosphorylation 
of tau causes it to accumulate within cellular aggregates, which are the hallmark 
of AD and FTD.  
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The roles of amyloid and tau in dementia are poorly understood, and it is 
unclear whether accumulation of misfolded protein is a primary driver of 
pathology or merely represent down-stream consequences of generalised 
cellular malfunction. There has been a recent shift of focus on the role that tau 
might play in both AD and FTD (Kametani and Hasegawa, 2018).  Several 
familial mutations in tau have been identified that can cause dementia without 
amyloid deposition (Wolfe, 2009), and tau aggregation appears to be more 
closely related to cognitive loss in AD (Huber et al., 2018). Studies have also 
demonstrated that suppression or deletion of tau has neuroprotective effects in 
AD models (Shipton et al., 2011). Finally, the focus on understanding tau 
pathology is further supported by unexpected failures trials of candidate drugs 
targeting β-amyloid (Doody et al., 2013, 2014; Salloway et al., 2014).  
 
  Astrocyte roles in dementia 
 
Astrocytes have long been implicated as playing a number of roles in AD and 
FTD pathology. Some genes identified as being associated with Alzheimer’s 
from genome-wide association studies (for example Apoe and Clusterin) are 
expressed more highly in astrocytes as compared to neurons (Cahoy et al., 
2008), and reactive and abnormal astrocytes are a well-established 
histopathological feature of AD (Chun and Lee, 2018) and FTD (Radford et al., 
2015).  
 43 
Astrocytes undergo morphological and functional changes, which can include 
both toxic gain-of functions as well loss of normal neuroprotective and 
homeostatic functions. Astrocytes react to misfolded protein aggregates such as 
β-amyloid in plaques and uptake β-amyloid via the low-density lipoprotein 
receptor-related protein 1 (LRP1) transporter, with astrocytes being implicated 
in both β-amyloid clearance and plaque spread (Liu et al., 2017). In AD, 
activated astrocytes surrounding plaques overexpress the serine protease 
inhibitor a1-antichymotrypsin (ACT). This protein has been suggest to inhibit 
β-amyloid breakdown and to induce tau hyperphosphorylation (Akiyama et al., 
2000; Padmanabhan et al., 2006).  
Astrocytes in AD demonstrate impaired calcium signalling. Picomolar amounts 
of β-amyloid induce intracellular calcium transients and spontaneous 
intercellular Ca2+ waves in cultured astrocytes and leads to upregulation of the 
reactivity marker Glial Fibrillary Acidic Protein (GFAP) (Lee, Kosuri and 
Arancio, 2014). Targeting activated astrocytes in the hippocampus of APP/PS1 
mouse model of Alzheimer’s with astrocyte-specific expression of VIVIT, an 
inhibitor of the calcineuron/NFAT signalling pathway, was shown to reduce 
glial activation and improve cognition (Furman et al., 2012).  In addition, 
astrocyte glutamate uptake capacity is impaired in AD, via mechanisms 
involving oxidative modifications of the glutamate transporters EAAT1 and 
EAAT2, in both patient brain samples and animal models (Beart and O’Shea, 
2009).  
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In contrast to AD, the consequences of astrocyte activation in tauopathy or FTD 
are less well understood.   Astrocytes in mutant-tau transgenic mouse models 
of FTD were found to have reduced glutamate transporter expression and 
transport capacity, along with reduced GLT-1 staining in tau-bearing astrocytes 
(Dabir, 2006).  And in an IPS-stem cell model of FTD, astrocytes expressing the 
N279K MAPT mutation demonstrated increased vulnerability to oxidative 
stress, with impaired antioxidant capacity, when co-cultured with neurons 
(Hallmann et al., 2017). Astrocytes in FTD-model transgenic mice have also 
been shown to demonstrate increased levels of markers associated with cellular 
senescence and clearance of senescent cells reduced tau-dependent pathology 
and improved cognition (Bussian et al., 2018). Finally, transplantation of 
healthy glial-precursors has been demonstrated to reduce disease severity in the 






Taken together, the above studies demonstrate the emerging concept that 
astrocytes are influenced by neurodegenerative processes and play important 
roles in mediating both toxic down-stream processes as well as having 
neuroprotective roles. However, the manner in which astrocyte phenotype is 
altered in dementia, as well as the consequence on neuronal health, is poorly 
understood.  
 
 Thesis aims 
In this introduction, I have summarised key roles that astrocytes play in health 
and disease, along with our current understanding of the cell-autonomous and 
non-cell autonomous signals that influence their function and phenotype. The 
signals that control astrocytes in normal physiology, and the consequences of 
neurodegeneration on astrocyte transcription, function and phenotype are 
incompletely understood.  
The overall aim of the work presented in this thesis was to better understand 
the non-cell autonomous signals that control astrocyte transcription and 
function in health and disease. This was to identify astrocyte neuroprotective 
signalling pathways that could be manipulated to enhance CNS resilience and 
reduce neuronal loss in neurodegenerative conditions such as dementia.  
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The first results chapter describes studies investigating how neuron-astrocyte 
interactions alter astrocyte transcription to drive metabolic capacity of 
astrocytes in vitro. The second results chapter expands upon this in vivo: 
examining how astrocyte transcription is influenced by synaptic activity in both 
a controlled light-stimulus paradigm, and a more complex (yet more clinically 
relevant) prolonged anaesthesia paradigm.  
The final results chapter investigates how astrocyte transcription is altered in a 
transgenic mouse model of human tauopathy and FTD. I describe how 
neurodegeneration drives wide-spread changes to astrocyte transcriptional 
signatures with alterations in antioxidant pathway genes. Enhancing expression 
of astrocyte antioxidant pathways achieves both transcriptional and functional 























2.1. Neuron and astrocyte cell-culture 
2.1.1. Rodent primary culture 
Primary cortical neurons and astrocytes were cultured from E17.5 CD1 mice or 
E20.5 Sprague Dawley (SD) rat embryos using a modified version of the protocol 
described by Bading and Greenberg, 1991. Cortices were dissected following 
decapitation in dissociation medium (DM) (mM: 81.8 Na2SO4, 30 K2SO4, 5.84 
MgCL2, 0.252 CaCl2, 1 HEPES, 0.001% Phenol Red, 20 Glucose, 1 kyurenic acid, 
adjusted to pH 7.35 with NaOH). Tissue was enzymically digested by incubation 
with DM with 10 units/mL papain enzyme (Worthington Biochemicals) for 40 
mins with regular mixing, followed by two washes with DM and two washes 
with Neurobasal-A medium (Thermofisher) supplemented with 1% rat serum 
(Envigo), 1 x B-27 supplement (Thermofisher), 1 x Antimicrobial-Antifungal 
supplement (premixed penicillin, streptomycin and amphotericin B - 
Thermofisher) and 1mM glutamine (Sigma). Following washing, cortices were 
mechanically dissociated with repeated mixing using a 5 mL serological pipette 
and the resulting cell-suspension diluted with in Opti-MEM  (Life Technologies) 
supplemented with glucose (20 mM) and Antimicrobial-Antifungal to achieve a 
final tissue concentration  of 0.14 mouse cortical hemispheres or 0.07 rat 
cortical hemispheres per mL.  
For neuronal culture, 0.5 mL of cell suspension was added to 24-well tissue-
culture plates (with or without glass-coverslips) coated with 0.5 mLs of water 
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with 0.5% laminin from mouse Engelbreth-Holm-Swarm sarcoma cells (Roche) 
and 1.33% poly-D-lysine (Sigma). For astrocyte culture, 10 mL of cell 
suspension was added to 75 cm tissue-culture flasks coated with 10 mL of water 
with 1.33% poly-D-lysine only. All plates and flasks were pre-coated with 
appropriate coating mixtures for 2 h at 37⁰C in a humidified 5% CO2 incubator 
and washed and dried prior to application of cell suspension.  
Plates and flasks with cell-suspension were incubated for 2.5 h at 37⁰C in a 
humidified 5% CO2 incubator. After this, plate or flask medium was aspirated 
(along with dead or non-adherent cells) and replaced with feeding medium. 
Neurons were fed with: 1 mL Neurobasal-A medium supplemented with 1% rat 
serum, B-27, Antimicrobial-Antifungal and glutamine as above as described 
above. Astrocytes were fed with Dubenco’s Modified Eagle Medium with 4.5% 
glucose, L-glutamine and Phenol Red (DMEM High Glucose – Thermofisher) 
supplemented with 10% heat inactivated fetal bovine-serum (Invitrogen) and 
1x Antimicrobial-Antifungal.  
Neuronal cultures were subsequently fed at day in vitro (DIV) 4 with 1 mL of 
Neurobasal-A medium supplemented with 1% rat serum, B-27, Anti-Anti and 
glutamine along with 9.6 μM of the antimitotic cytosine B-D-arabinofuranoside 
hydrochloride (AraC) to prevent glial growth. Astrocyte cultures were fed at 
DIV4 with 10mLs of DMEM supplemented with 10% FBS as above.  
Astrocytes were split 3:1 (by washing with 1 x PBS, followed by detachment 
using 0.05% trypsin-EDTA (Life Technologies), twice at DIV 7 and DIV 11 to 
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achieve >95% GFAP positive pure astrocyte cultures.  For co-culture astrocytes 
were plated onto 24 well plates at astrocyte DIV 11, and primary neurons were 
cultured on top of confluent astrocytes 72 h later. Neuron-astrocyte cocultures 
were kept in serum-free medium (Neurobasal A supplemented with B-27, Anti-
Anti and glutamine as above) and fed every 3-4 days. Co-cultures were utilised 
for experiments at neuronal DIV 9 (Astrocyte DIV 23) unless otherwise stated.  
2.1.2. Human astrocytes 
 
Primary human astrocytes were obtained from ScienCell Research Laboratories, 
and cultured in human astrocyte medium (ScienCell) for up to 5 passages in a 
similar manner to rodent astrocytes described above.  Induced pluripotent 
stem-cell derived astrocytes were generated and maintained as previously 
described (Serio et al., 2013).  In brief, neural precursor cells obtained from 
human-derived induced pluripotent stem-cells were cultured as neurospheres 
suspended in medium enriched in epidermal growth factor (EGF) and leukemia 
inhibitory factor (LIF) for four to six weeks.  After enrichment, neurospheres 
were enzyme- dissociated to a single-cell monolayer of astroprogenitor cells, 
and differentiated into mature human astrocytes by culturing with cilliary 
neurotrophic factor (CNTF). This process yielded cells with >95% positive for 
astrocyte markers (GFAP, s100B or aldh1l1) and < 2% of cells positive for 
neuronal markers (beta-3-tubulin). 
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2.1.3. Drug stimulations 
Conditions of altered synaptic activity in co-cultures were generated by 
changing cells into serum-free base-medium (10% minimum essential media 
(MEM, Life Technologies) and 90% salt–glucose–glycine (SGG) containing in 
mM: 114 NaCl, NaHCO3, 5.292 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 1 Glycine, 
30 Glucose, 0.5 sodium pyruvate, 0.1% Phenol Red) with 100nM tetradotoxin 
(TTX, Tocris) on DIV8 for 22 h to inhibit neuronal action potential firing. Cells 
were then washed and changed into medium containing 50 μM Bicuculline 
(BiC, Tocris) to induce network bursting. Control conditions were washed with 
TTX and left in medium containing BiC in the presence of TTX to maintain 
activity inhibition.  
 
2.2. Transfection 
Astrocyte specific transfection was achieved by transfecting confluent astrocytes 
24 h prior to neuronal co-culture. Cells were incubated for 45 mins in 
DNA/lipofectamine mix (0.65 μg total DNA with 2.33 μL of Lipofectamine 2000 
(Life Technologies) per well) in serum free transfection medium (in mM: 114 
NaCl, 26 NaHCO3, 5.3 KCl, 1 MgCl2, 2 CaCl2, 10 HEPES, 1 glycine, 30 glucose, 
0.5 sodium pyruvate, 0.001% phenol red, 1% Antibiotic-Antimitotic, 1% 
insulin–transferrin–selenium supplement (Thermofisher Scientific)). Following 
transfection, the lipofectamine-DNA mix was washed off and medium replaced 
with DMEM supplemented with 10% FBS and Antibiotic-Antimitotic as above.  
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Table 2-1 – References and sources for plasmids  
Glucose FRET (FLII12Pglu-700μδ6) Takanaga, Chaudhuri and Frommer, 2008 
Pyronic FRET San Martín et al., 2014  
Laconic FRET Barros et al., 2013 
VP16-CREB Klemm et al., 2001 





For cell culture: cells were fixed with 4% paraformaldehyde (PFA) for 20 mins 
at RT, washed 3x with PBS, and permeabilized for 5 mins with 1% NP40 (Life 
Technologies). For cortical slices: Mice were killed by perfusion-fixation with 
4% PFA. Brains were removed and 50 μM slices prepared using a vibratome. 
Slices were washed 3x with PBS, blocked and permeabilized with 10% normal 
goat-serum (Thermofisher) with 0.3% Triton-X (Sigma-Aldrich). Primary 
antibodies were applied overnight at 4⁰C whilst shaking, and secondary 
antibodies applied for 2hr at RT. Following this, cells or slices were washed 4x 
in PBS and mounted using Vectashield with 4′,6-diamidino-2-phenylindole 
(DAPI) (Vector Labs).  
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Table 2-2 Antibodies used for imaging 
Antibody Source Code Concentration  
Anti-GFP-FITC (goat) Abcam Ab6662 1:500  
Neuro-chrom™-CY3 (rabbit) Millipore Abn2300c3 1:500  
Anti- ALDH1L1 (rabbit) Abcam Ab190298 1:500  
Anti-Rabbit IgG-CY3 (donkey) Jackson 711-165-152 1:500  
 
2.3.2. Quantifying astrocyte perimeter 
 
Changes in GFP-transfected astrocyte complexity in monoculture and co-
culture was determined by taking cells at DIV0 vs DIV9, and an outline mask 
created using Adobe Photoshop. The area and perimeter measurements of the 
outline mask were determined and ratios calculated.  
 
2.3.3. FRET metabolic imaging 
FRET and fluorescence imaging was carried out on a Leica AF6000 LX 
microscope utilising a DFC350 FX digital camera operated using the LAS X 
imaging suite. All FRET imaging was performed at 37⁰C in continuous perfusion 
with artificial-CSF (composition in mM: 150 NaCl, 3 KCl, 10 HEPES buffer, 0.1 
glycine, 2 CaCl2, 1 MgCl2, and 10 glucose, pH 7.4). Tetrodotoxin (TTX) 100 nM 
was added to A-CSF perfused in all conditions to exclude acute effects of altered 
neuronal activity on astrocyte metabolism at the time of imaging. Imaging was 
carried out at 20X magnification and images were acquired every 10 s. All 
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probes were imaged with a standard FRET CFP/YFP filter wheel, with excitation 
at the CFP spectrum (472±5 nm) and measurements taken within both CFP 
(472±15 nm) and YFP (542±13 nm) emission spectra.  
For glucose measurement, the YFP/CFP ratio of FLII12Pglu-700uδ6 FRET probe 
was used to determine intracellular glucose concentrations for individual 
astrocytes. Levels were measured at baseline in ACSF with TTX, before the 
addition of the glucose-uptake inhibitor cytochalasin B (20 μM) after 60s, 
resulting in a reduction in intracellular glucose levels corresponding to the rate 
of glucose consumption.  
For pyruvate and lactate measurements, the CFP/YFP ratio of the Laconic and 
Pyronic FRET probes were used to determine intracellular lactate and pyruvate 
levels respectively. Levels were measured at baseline in ACSF, before the 
addition of the MCT inhibitor AR-C155858 (1 μM) resulting in an increase in 
concentration corresponding to lactate or pyruvate production. 
All FRET ratios were normalised by subtracting baseline and expressed as 
percentage of maximum. A linear least-squares fitting routine was used to 
determine the line of best fit and slopes calculated for the portion of the curve 




2.4. Western blots 
Cell-culture and tissue samples were lysed in RIPA-buffer (500 μL per half-
cortex; 40 μL per well of 24-well tissue-culture plate) followed by centrifugation 
to remove non-lysed debris.  A BCA assay (see below) was utilised to calculate 
protein concentrations of lysate. Protein concentration was adjusted and mixed 
with 4x LDS Sample Buffer (Thermofisher) and 10x Nupage Sample Reducing 
Reagent (Life Technologies) to achieve 1 μg/μL of protein and samples boiled at 
100⁰C for 10 mins,  15 μg of protein were loaded onto 4-12% pre-cast gradient 
Bis-Tris gels (Nupage, Life Technologies) and electrophoresis performed using 
the XCell SureLock system at 120V, in MOPS running buffer (in mM: 50 3-(N-
morpholino)propanesulfonic acid (MOPS), 50 
tris(hydroxymethyl)aminomethane (TRIS), 1 EDTA, 3.5 SDS, pH adjusted to 
7.7).  
Proteins were transferred onto a PVDF membrane (Millipore) by 
electrophoresis at 80V for 1h in transfer buffer (in mM: 96 glycine, 12 mM Tris, 
20% Methanol).  Membranes were blocked in Tris-buffered saline (TBS) (in mM: 
20 Tris, 137 NaCl and 0.1% Tween-20, pH 7.6, 5% milk) and incubated with 
primary antibody overnight at 4⁰C. The following day, membranes were washed 
in TBS three times and incubated with HRP-conjugated secondary antibody for 
1 h at RT. For reprobing, membranes were stripped for 15 mins using ReBlot 
PLUS Strong (Merck Millipore), re-blocked with 5% milk TBS with tween for 1 
h, before repeat primary antibody incubation as above.  
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Bands were visualised using peroxide and LumiGlo (Cell Signalling), and 
photographed on Kodak X-Omat film (Sigma). A range of exposures were 
utilised to ensure both that bands were not saturated and that faint bands were 
not missed.  Developed photographs were digitally scanned (greyscale, 600dpi) 
and densitometric quantification performed using ImageJ, with subtraction of 
background and normalisation of band density performed using a β-actin 
control for each well.  
 
Table 2-3 Antibodies used for Western blots 
Antibody Source Code Concentration 
Anti-Cleaved - Caspase 3 (Rabbit) Cell-Signalling #9664 1:1000 
Anti-Caspase-3 (Rabbit) Cell-Signalling #9665 1:1000 
Anti-β-Actin (Rabbit) Abcam Ab8227 1:20000 
Anti-rabbit IgG – HRP (Goat) Cell Signalling #7074 1:2000 
 
2.5. Bicinchoninic acid (BCA) assay  
Protein concentrations were measured using the Pierce BCA assay 
(Thermofisher) as per instructions. 50 μL of lysate was transferred in triplicate 
to a clear flat-bottomed 96 well plate, along with 50 μL of known bovine-serum 
albumin standards, and 200 μL of BCA protein re-agent mixture added.  The 
plate was covered and incubated at 37⁰C for 30 mins, and absorbance measured 
at 562 nM using the Lumistar Omega plate reader.  
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2.6. Caspase-GLO Assay 
Activated caspase 3 and 7 activity was measured using the Caspase-Glo™ 3/7 
luminescence assay (Promega) as instructions. 50 μL of normalised tissue 
extract (1 μg/μL protein) was added to 96 well plates in triplicate, along with 
samples from negative and positive apoptosis controls (cultured cells exposed 
to 24h of 100nM staurosporin). 50 μL of reconstituted Caspase-Glo reagent was 
added, and mixed gently at RT for 30 secs. The plate was incubated at RT for 1h 
and luminescence measured using a plate reader.  
 
2.7. Fluorescence-activated cell sorting 
CNS cell suspensions were prepared by enzyme and mechanical dissociation of 
mouse cortices as described above, with final resuspension in 10 mLs Hibernate 
A (Thermofisher) + 1% rat serum + B27 + A/A at 4⁰C.  Suspensions were sorted 
using a FACSAria IIiu flow cytometer (Beckton Dickinson Immunocytometry 
Systems (BD), UK) running BD FACSDiva v6 software.  An electronic acquisition 
gate was applied to the Forward/Side scatter plot to exclude debris from intact 
material.  Aggregates were excluded by applying gating to the FSC area vs width 
profile. EGFP was detected following 488 nm excitation, at emission between 
530/30nm and an electronic gate applied to identify positive cells by reference 
to a negative control.  
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Cells were acquired at ~12,000 events per second and positive cells were sorted 
using a 85 µm nozzle at a system pressure of 45 psi into 15 mL collection tubes 
pre-filled with 5 mL Hibernate A medium supplemented with 20% bovine 
serum. Sort purity was verified by the reacquisition of 1,000 singlets from the 
collection tubes. Post-acquisition data was gated and analysed using FacsDiva 
v6 software. 
 
2.8. RNA analysis 
2.8.1. RNA extraction 
RNA extraction was carried out using the High Pure RNA Isolation Kit (Roche) 
as per manufacturer’s instructions. 3 wells of a 24 well cell-culture plate were 
lysed per sample and transferred into glass-fibre filter column assemblies. 
Following DNAse incubation for 15 minutes, the columns were washed, dried 
and RNA eluted in 30 μL of elution buffer. 
Low-yield RNA extraction (for example following ribosomal pulldown) was 
carried out using the Absolutely RNA Nanoprep kit (Agilent) as per 
manufacturer’s instructions. Samples were lysed in 100 μL of lysis buffer with 
β-mercaptoethanol; mixed with equal volume of 80% sulfolane and added to  
silica-based fibre filter columns. DNAse treatment was carried out for 15 mins; 
columns were washed and dried, and RNA eluted in 20 μL of pre-warmed 60⁰C 
RNAse free water. 
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2.8.2. Translating Ribosome Affinity Purification (TRAP). 
Isolation of cell-type specific translating mRNA was carried out as previously 
described (Heiman et al., 2014). Briefly: tissue or cells were lysed in ice-cold 
lysis buffer (in mM: 20 HEPES, 10 MgCl2, 150 KCl, 0.5 DTT) along with 100 
μg/mL cyclohexamide (Sigma), cOmplete ULTRA protease inhibitors (Sigma) 
and RNAse inhibitors (Superasin – Life Technologies; RNAsin – Promega). Cell 
lysate was centrifuged to clear debris and solubilised with 1% NP40 and 30 mM 
1,2-diheptanoyl-sn-glycero-3-phosphocholine (DHPC – Avanti Polar Lipids). 
Following further centrifugation, supernatants were added to pre-prepared 
anti-GFP (19C8 and 19F7 antibodies – Sloan Kettering Memorial Centre) coated 
magnetic beads (Dynabeads MyOne Streptavadin T1 – Life Technologies). 
Following immunoprecipitation overnight at 4⁰C with continuous rotation, 
beads were washed four times. Cell-type specific mRNA, attached to 
immunoprecipitated GFP-tagged ribosomes, was isolated and purified using the 
Agilent Nanoprep kit described above. 50 μL of solubilised lysate (“input 
sample” – representing total RNA) was taken prior to immune-precipation and 
spun overnight at 4⁰C (same conditions as TRAP samples) before RNA-
purification with TRAP samples.  
2.8.3. Reverse-transcription PCR (rtPCR) 
cDNA was generated using the Transcriptor First Strand cDNA Synthesis Kit 
(Roche). 7 μL of RNA was added to the RT and buffer mixture prepared with 
random hexamers and oligoDT primers as per kit instructions, and rtPCR 
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carried out with the following programme: 10 min at 25°C, 30 min at 55°C and 
5 min at 85°C.   
2.8.4. Quantitative PCR (qPCR) 
qPCRs were performed on a Mx3000P QPCR machine (Agilent Technologies) 
using the FastStart Universal SYBR Green QPCR Master (Rox) (Roche) reagent. 
6 ng of cDNA was used for each reaction and all qPCR results were carried out 
in duplicate or triplicate, along with no template controls and no RT controls 
where appropriate. The following cycling programme was used: 10 min at 95°C; 
40 cycles of: 30 s at 95°C, 40 s at 60°C (with fluorescence detection), 1 min at 
72°C;  ending with dissociation curve: 1 min at 95°C and 30 s at 55°C with a 
ramp up to 30 s at 95°C with fluorescence detection. All data was normalised to 
house-keeping gene controls (Rpl13a). 
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Table 2-4 Mouse-specific primer sequences 
Gene Forward (5’-3’) Reverse (5’-3’) 
Aif1 GCAATGATGAGGATCTGCC CCACTGGACACCTCTCTAATTAATC 
Aldh1l1 GTTGCTAGCCCAGAGCC GGAACTTAAACACGGGCAC 
Aqp4 GAGAGTCGTCACACCAGTG TCCCAGCCAGGAAGTAACTA 
Arc AGTGGTGGGAGTTCAAGCAG TCCTCAGCGTCCACATACAG 
Bdnf AAAGTCCCGGTATCCAAAGG CTTATGAATCGCCAGCCAAT 
Cx3cr1 CTGGTGGTCTTTGCCTTC GCACTTCCTATACAGGTGTCC 
Dio2 CCCTTCTGAGCGAATTGATCCA CACATCGTAAGTATGTATCTGGG 
Eno2 GCCATCTCCTGTAACTCTCC ATTCTGTAAAGTTCCGAGCTTC 
Fos CCATGATGTTCTCGGGTTTC TGGCACTAGAGACGGACAGA 
Gfap GCAAAAGCACCAAAGAAGGGGA ACATGGTTCAGTCCCTTAGAGG 
Hes5 TGCAGAGTTGTCATTTGGGG AACGGGCCCTGAAGAAAGT 
Hey2 GAATGTAACGTAGCACAAGATCAG AGGTCTTTCGACTTAATTTCCC 
Hk2 GTTCCCTCCCCTGTTCTAC TCCTCTTCCTCCTCCTCC 
Ldha GTACAGTGGTGTTGAGATGGTG CAGGGCAGCAATGCAG 
Mbp CCAGTCTAATAATGTCCATCGAC CAGATTAACAAGATGCAGTATTGG 
Mog AAAGAATACCGACCAGAGAAATAC CACATTGGTTCTCAGAGAAATAAG 
Npy AGACCTCTTAATGAAGGAAAGCAC CAGGCAGACTGGTTTCAGG 
Ptg CTGCGTGAACAGGACAAG GACAGTGTGGAGCGGAC 
Rpl13a GATGAATACCAACCCCTCC CGAACAACCTTGAGAGCAG 
Slc1a2 TATCATCTCCAGTTTAATCAC TTCATTCAACATGGAGATGACC 
Slc1a3 CAAGACACTGACACGCAAGGAC CTTAACATCTTCCTTGGTGAGGC 
Slc2a1 TGCAGCCCAAGGATCTC TGAATATCCTCCTGGACTTCAC 
Slco1c1 GATCCAGACCCTTGCGAACAT GATATCCGACTGTAAAGGATGG 
Tubb3 CCGACAACTTTATCTTTGGTC TCCACCACAGTGTCCG 
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Table 2-5 Human specific primer sequences 
Gene Forward (5’-3’) Reverse (5’-3’) 
ALDH1L1 CTCCCTCTTGAGCCTGG GACGGTCTCTCTTCAGAAGC 
AQP4 GAGAGTCGTCACACCAGTG TCCCAGCCAGGAAGTAACTA 
HES5 TCTTCTGCCAAGTGTCTGAC CCGGCACTACAAATATCATAGA 
HEY2 TGAGAGAGTCGTGTTTCGTAAG CAACTTGAAAATTATTTTCAGCAG 
HK2 TTATAAGATGTCATCCCCTTGTG TGATGCATGTGAACAAATCC 
LDHA GGAAAAACATCAACTCCTGAAG CACACGGTAAACATCCACC 
PFKFB3 GCGAAAGAAGGGGGAC CTGTAGGGTCGTCGCAC 
PPP1R3C GGGAGGTCTGATCATTGTTG AATACCACCCACATTCTTAAAGG 
RPL13A CCACTACCGGAAGAAGAAACAG CAGGGCAACAATGGAGG 
SLC16A3 CCACTGCTATGCTCAAGG CACTCAAGAGGGGTGGG 
SLC1A2 TTATTTATGTTCGGTTTGCCT CTAGGACGATGAGATGATGACT 
SLC1A3 ACCTGCCCTCTGTTTCC ATGAATAATCCCACTCCTGG 
SLC2A1 TTCCAAACCTGACAGATGTC GTGGGCACAGGAGACTC 
SLCO1C1 GATCACACAGACTACCAAACAC GTTTGTACGTCACCATGCCG 





Total RNA sequencing was performed by Edinburgh Genomics using Trueseq 
Stranded Total RNA V2 library preparation along with next-generation 
sequencing on the Illumina Novaseq 6000 platform. At-least 1 μg RNA per 
sample was utilised, with RNA-integrity number (RIN) > 7. TRAP-sequencing 
(along with sequencing of matched inputs where appropriate) was performed 
by Cambridge Genomic Services, utilising the Clonetech - SMART-Seq v4 Ultra 
Low input RNA library preparation, along with sequencing on the Illumina 
Nextseq 500 platform. At least 1ng RNA was used per sample with RIN > 7. All 
sequencing utilised 75 paired-end reads at the following requested depths: 
Table 2-6 Requested depth for RNA-sequencing 
Experiment Approximate sequencing  
depth (per sample) 
Light Stimulus TRAP Input: 50 million 
TRAP: 30 million 
Co-culture Mixed-species TRAP Input: 60 million 
TRAP: 30 million 
Anaesthesia TRAP Input: 60 million 
TRAP: 30 million 
P301S TRAP Input: 60 million 
TRAP: 30 million 




Bioinformatics was performed by Owen Dando and Xin He. RNA-seq reads were 
mapped and analysed using Spliced Transcripts Alignment to a Reference 
(STAR) version 2.5.3a. Subsequently, per-gene read counts were summarised 
using featureCounts version 1.5.2. For read-mapping and feature counting, 
genome sequences and gene annotations were downloaded from Ensembl 
version 94. Differential expression analysis was then performed using DESeq2 
(R package version 1.18.1), with a significance threshold calculated at a 
Benjamini–Hochberg-adjusted P value of <0.05.  
Gene Ontology enrichment analysis on differentially expressed genes was 
performed with topGO (R package version 2.30.1), using gene ontology 
annotations described by the R package org.Mm.eg.db  (version 3.5.0), using 
the Fisher's exact test statistic. The "weight01" graph processing algorithm was 
used to improve relevance of results. 
Mixed-species sorting was carried out using the SARGASSO (Sargasso Assigns 
Reads to Genomes According to Species-Specific Origin) python tool as 
described in Hasel et al., 2017 and Qiu et al., 2018 (source code available: 
http://statbio.github.io/Sargasso).  This utilises a strategy that aims to minimize 
reads misallocated to the incorrect species whilst maximizing the number of 
reads unambiguously assigned to the correct species. Briefly, the protocol first 
maps reads to the genomes of each species. All reads that map to mouse genome 
and not to rat are provisionally assigned to the mouse, and vice-versa. If 
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alignments to both genomes exist, these alignments are examined in more 
detail, including examining the number of mismatches, and the structure of 
read alignments, along with further checks, to finally assign reads with high 
confidence to each species, whilst rejecting ambiguous reads.  
For analysis seeking to discover genes altered differentially at the level of 
translation compared to transcription by experimental conditions, per-gene 
read counts were modelled with DESeq2. In short, read counts were modelled 
with generalized linear models of the negative binomial family, as is standard in 
differential gene expression studies. A model design was used containing main 
effects of experimental condition (for example, mono or coculture), sample type 
(input or TRAP) and an interaction term between experimental condition and 
sample type. Genes with different translation and transcription behaviour were 
then discovered by testing for statistical significance of this interaction term, 
using a significance threshold of adjusted p-value of <0.05.  
Analysis of transcription factor enrichment was carried out using the 
Gene2Promoter tool (Genomatix Software GmbH, Munich). Promoter regions 
were selected using Genomatix optimised lengths (1000 bp upstream of first 
transcription start site (TSS) and 100bp downstream of last TSS) from genes 
upregulated >2 fold in response to treatment conditions, and analysed for 
statistical overrepresentation of transcription factor binding sites using 




2.9. In vivo methodologies 
2.9.1. Animal husbandry 
All procedures described were performed in compliance with the UK Animals 
(Scientific Procedures) Act 1986 and University of Edinburgh regulations, and 
carried out under project license numbers 70/9008 and P1351480E. Mice were 
group-housed in environmentally-enriched cages within humidity and 
temperature controlled rooms, with a 12-hour light dark cycle (unless otherwise 
stated), with free access to food and water.  
2.9.2. Transgenic mouse lines 
The Aldh1l1-EGFP-Rpl10a (referred to as astro-TRAP in this thesis) transgenic 
mouse line expresses an EGFP-tagged ribosomal protein l10a under the 
astrocyte-specific aldh1l1  promoter,  was generated as previously described 
(Doyle et al., 2008) and re-derived on a C57B/6 background from frozen sperm 
imported from Jackson Laboratories (Mouse Strain Number – 030248). Animals 
were utilised as heterozygotes in all experiments and mixed-sex unless 
otherwise stated.   
The Thy1-hTau.P301S (referred to as P301S in this thesis) transgenic mouse 
line over-expresses human mutant P301S tau under the neuron-specific Thy 1.2 
promoter and was generated as previously described (Allen et al., 2002). Female 
mice were used for all experiments as they both demonstrate less fighting and 
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exhibit more rapid-onset pathology than males.  Animals were used as 
homozygotes at 12 or 20 weeks for experiments described in this thesis, or 
culled humanely if they demonstrated rapidly progressive pathology (20% body 
weight loss persisting for 48 hours or hind limb paralysis). Mice were culled by 
perfusion with ice-cold PBS with cyclohexamide, followed by rapid dissection of 
the superficial frontal cortices and cervical spinal cord (C2 – C7 vertebral levels).  
2.9.3. Light stimulus experiments 
4 week or 24 week old mice were transferred from standard lighting conditions 
to a temperature and ventilation controlled light-proof cabinet and housed in 
constant darkness for 7 days. Mice were then exposed to a further 24 h of 
darkness or 24 h of continuous light, following which they were decapitated and 
visual cortices rapidly dissected.  
2.9.4. Prolonged anaesthesia 
8 week old mice were induced in an anaesthesia chamber with 4% isoflurane in 
oxygen, followed by maintenance anaesthesia via facemask with 1.5 % 
isoflurane. Mice were actively warmed to 36⁰C, and temperature, pulse, 
respiratory rate and oxygen saturations continuously monitored and 
maintained within normal physiological range using the Physiosuite monitoring 
system (Kent Scientific). 0.1 mL subcutaneous warmed sterile 0.9% saline 
solution was administered every 1-2hrs to maintain hydration. 
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2.9.5. Transcranial electrical stimulation 
Mice were anaesthetised and monitored as above. A small area of scalp above 
the right cortex and left cheek was shaved. Silver-wire electrodes were applied 
using electrode conducting gel (SignaGel – Parker Labs). Sinusoidal alternating 
current was applied at 20 min intervals via a NeuroConn DC Stimulator Plus 
device (NeuroCare Group, Germany) using a 10Hz frequency, with a 10 cycle 
fade-in and fade-out period. A ramp period of 100 μA for 5 mins followed by 
250 μA for 5 mins was used before a final stimulation current of 500 μA.  
 
 Statistics and data analysis 
Unless otherwise stated, all data are presented as mean, with error bars 
representing standard-error of the mean. Statistical tests used to analyse each 
result are detailed in figure legends. In general, comparisons between two 
means were made using two-tailed t-tests: unpaired for independent data, and 
paired for non-independent data. Comparisons between groups were made 
using 1-way or 2-way ANOVA, with correction for multiple comparisons with 
the Dunn-Sidak method. A significance level of p < 0.05 was used.  
In RNA-sequencing experiments, significantly changed genes were selected as 
those: i) expressing >1 FPKM expression in any condition;  ii) achieving 
significance threshold calculated at a Deseq2 Benjamini–Hochberg-adjusted p-
adjusted value of < 0.05 as outlined above; and iii) demonstrating greater than 
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1.3 fold change. Statistical analysis was done using Graphpad Prism v7.0 for 









Synaptic activity regulates 
astrocyte transcription to 
control metabolism.  
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3.1. Chapter Introduction 
The consequences of activity-dependent neuron-to-neuron signalling for the 
CNS have been extensively studied. Synaptic activity alters neuronal 
transcription, and drives cellular and circuit-level changes necessary for 
memory and neuronal health (Hardingham et al., 2018).  Non-cell autonomous 
signals from neurons to astrocytes were also implicated to have important 
consequences for CNS homeostasis and function. However the manner in which 
neuron-astrocyte signalling influences astrocytes was not fully understood.  
In this chapter, I describe investigations seeking to understand how neurons 
and synaptic activity alter astrocyte transcription. A key challenge in 
understanding non-cell-autonomous signalling between different cell-types is 
the requirement to physically separate cells before transcriptomic analysis. 
Several approaches have been traditionally used. Co-culturing astrocytes and 
neurons utilising membrane-inserts allows cell-types to be physically separated 
whilst allowing diffusion of soluble messengers (Habas et al., 2013). However, 
this prevents direct cell-cell interactions. Other powerful and useful methods 
that can be used include flow-cytometry sorting, magnetic sorting and single-
cell sequencing.  However these methods are susceptible to contamination from 
off-target cell-types and require tissue to be dissociated into a single-cell 
suspension prior to RNA-extraction, which can induce transcriptional stress 
responses (Liu, Morgan and Pine, 2014).  
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A novel technique recently developed by our lab exploits inter-species 
differences in RNA sequences between closely-related species to separate and 
assess the transcriptional responses of cocultured cells in silico (Qiu et al., 
2018).  Rat neurons are cocultured with mouse astrocytes, and RNA-seq reads 
separated according to species (and hence cell-type) post sequencing. This 
approach allows the investigation of the interactions between co-cultured 
astrocytes and neurons, without the use of physical separation prior to analysis. 
Data from this approach revealed that neurons induced wide-spread 
transcriptomic changes in astrocytes both as a result of direct cell-to-cell 
contact with neurons, as well as further transcriptomic changes induced by 
altered synaptic activity (Hasel et al., 2017) (Figure 3.1). 
In this chapter, I validated findings from the above study (done on mouse 
astrocytes) in a human-astrocyte coculture system and describe conservation 
between human and mouse astrocytes in the transcriptional response both to 
direct neuronal contact and altered synaptic activity.  
The largest family of upregulated genes due to synaptic activity are involved 
with astrocyte metabolic flux, with upregulation of key components of the 
astrocyte-neuron lactate shuttle. I proceed to demonstrate, using intracellular 
metabolic optical FRET probes, the manner in which synaptic activity alters 




signalling pathway in driving activity dependent transcriptional and metabolic 
changes.   





Figure 3.1 - Neurons and neuronal activity alter a wide-
programme of mouse astrocyte transcription. (Figure modified 
from Hasel et al., 2017). A. Neurons alter mouse astrocyte 
transcription. Mouse astrocytes were kept as monoculture or 
cocultured with rat neurons for 9 days. RNA was extracted and species-
specific gene expression analysed using the SARGASO species-sorting 
work flow. Coculture with rat neurons alters the expression of a large 
number of astrocyte genes. B. Synaptic activity alters mouse 
astrocyte transcription. Mouse astrocytes cocultured with rat 
neurons were transferred into TTX-containing medium for 22h, after 
which cells were washed and transferred to medium with either 
bicuculline (BiC) to create network firing or remained in TTX 
(BiC+TTX) to achieve silent neurons. RNA was extracted at 16 h post-
wash.  Expression of genes (FPKM) in astrocytes in the presence or 
absence of neurons is plotted for all genes expressed >0.5 FPKM 
average across mono- and co-cultures. Red and black crosses indicate 
the astrocytic genes induced or repressed by neurons more than 




 Co-culture with neurons alters human astrocyte morphology 
and gene expression. 
 
It is well established that neurons alter rodent astrocyte morphology. However, 
there are significant inter-species differences between human and rodent 
astrocytes. Human astrocytes are larger and more complex, with increased cell 
volume. They have an increased number of processes, and make contact with a 
greater number of synapses (Oberheim et al., 2009). 
I therefore asked to what extent the transcriptomic changes induced in 
astrocytes in response to neurons were conserved between rodents and humans. 
I developed and characterised an in vitro co-culture system in which primary 
human astrocytes were co-cultured with rat neurons.  By transfecting astrocytes 
with green-fluorescent protein (GFP) prior to co-culture, I visualised and 
measured morphological complexity and found that co-culture with neurons 
dramatically alters human astrocyte morphology. (Figure 3.2 A, B). Astrocytes 
become more complex and resemble in vivo astrocytes, in a manner similar to 
rodent astrocytes (Hasel et al., 2017). 
I next investigated whether coculture with neurons induced similar changes to 
human astrocyte gene expression as in mouse astrocytes. I designed and 
validated human-specific primers for specific genes that were found to be most 
upregulated in mouse astrocytes with rat neuronal coculture, and used 
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quantitative PCR (qPCR) to assess the response of these genes in human primary 
astrocytes co-cultured with rat neurons. Coculture with neurons pushes human 
astrocytes towards a more mature state, with upregulation of genes that act as 
markers for maturity (glutamate transporters Slc1a2, Slc1a3 and the water 

























































































Figure 3.2 - Neurons alter human astrocyte morphology and gene 
expression. A, B.  Human primary astrocytes co-cultured with rat neurons 
for 9 days undergo morphological changes leading to increased complexity (n 
= 12 in each group from three independent cultures, ***p<0.001 - two-tailed 
t-test).  C. Neurons induce gene expression changes in human astrocytes.  
Astrocyte gene-expression changes were analysed using human-specific 
primers and compared with astrocytes kept in monoculture. Neurons 
upregulate genes for notch signalling (Hes5, Hey2) to increase astrocyte 
maturity markers for glutamate uptake (Slc1a2, Slc1a3), thyroid hormone 
uptake (Slo1c1) and water regulation (Aqp4) (N=5, *p < 0.05 - 2-way ANOVA 
with Sidak’s correction for multiple comparisons).    
 
 78 
 Synaptic activity alters gene expression in human astrocytes 
Using the coculture system developed and characterised above, I next addressed 
whether altered synaptic activity altered human astrocyte gene expression. To 
alter neuronal activity, cocultured cells were incubated overnight in 
tetrodotoxin (TTX), to block neuronal firing. Cells were then washed in the 
presence of bicuculline (BiC- a γ-aminobutyric acid-A (GABA-A) receptor 
antagonist), to achieve increased action potential firing (confirmed using 
electrophysiology - Appendix Figure 7.1). Cocultures were either exposed to 
15 h of bicuculline to achieve high activity or washed with and kept in TTX to 
maintain electrically quiescent neurons. Following this, RNA was extracted and 
astrocyte-specific gene expression measured using human-specific primers with 
qPCR.  
I selected genes that were demonstrated to be significantly upregulated by 
synaptic activity in mouse astrocytes from our previous RNA-seq data. I found 
that increased synaptic activity upregulates the same genes in human astrocytes 
– with upregulation of gene-sets responsible for key homeostatic pathways 
including thyroid hormone activation (Dio2, Slco1c1), antioxidant protection 
(Sod3) and glucose uptake and metabolism (Pppc1r3c, Ldha, Slc1a2) (Figure 
3.3).  
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Figure 3.3 - Neuronal activity alters human astrocyte gene 
expression. Primary human astrocytes were co-cultured with rat 
neurons and cocultures stimulated to create conditions of high vs low 
neuronal activity.  Cells were exposed to tetradotoxin (TTX) overnight 
to suppress neuronal activity. TTX was then either replaced with 
bicuculline (BiC) for 15hrs to generate a condition of high neuronal 
activity or left on (TTX+BiC) to generate reduced neuronal activity. 
Human-specific primers were used to assess changes in astrocyte gene 
expression. Increased neuronal activity upregulates human astrocyte 
genes for thyroid hormone activation (Dio2 and Slco1c1)¸ antioxidant 
protection (Sod3), and glucose uptake and metabolism (Slc2a1, 
Ppp1r3c, Ldha) (N=3, * = p < 0.05, 2-way ANOVA with Sidak’s correction 
for multiple comparisons). 
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 Neuronal activity increases astrocyte metabolic flux.  
Having determined that human and mouse astrocytes demonstrated 
conservation in their morphological and transcriptional response to neuronal 
signals, I next set out to investigate if transcriptional changes led to alterations 
in astrocyte function.  
 The largest battery of genes upregulated by synaptic activity consisted of genes 
involved in the astrocyte-neuron lactate shuttle pathway (ANLS). Strikingly, 
every single step along this pathway had genes that were upregulated between 
50% - 200% , including genes for astrocytic glucose uptake, glycolysis and the 
production and export of lactate (Figure 3.4). In total, out of 32 genes involved 
in glycolysis and lactate export (wikipathways.org), 14 were significantly 
upregulated (p_adj < 0.05, fold-change >1.3), and a further 6 genes (total of 20 
genes) were trending upwards using less strict criteria (>1.2 fold change only). 
The mean fold change across all glycolytic genes was an increase of 1.33 fold.  
In contrast genes involved in mitochondrial import of pyruvate or the astrocyte 
Kreb’s cycle were unaltered. Out of a total of 95 genes involved in mitochondrial 
function, Kreb’s cycle and oxidative phosphorylation, none were significantly 
upregulated (p_adj < 0.05, fold-change >1.3), and only 2 were upregulated using 
less strict criteria (>1.2 fold change only). The mean fold change across all 
mitochondrial genes was 0.97. These data suggested that neuronal activity had 
a specific effect on the astrocyte-neuron lactate shuttle pathway, boosting the 
ability of astrocytes to provide fuel for metabolically active neurons.  
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Figure 3.4 - Synaptic activity increases astrocyte expression of 
genes in the astrocyte-neuron lactate shuttle pathway. (Figure 
from Hasel et al., 2017). Mouse astrocytes co-cultured with rat neurons, 
and gene expression assessed using RNA-seq and in silico read 
separation. Genes in red were significantly upregulated (deseq2 
padj<0.05). Neuronal activity enhances genes along each step in 
glucose uptake, glycolysis, and conversion of pyruvate to lactate and 
lactate export.  
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Given these transcriptional changes, I wanted to confirm whether synaptic 
activity drove a functional increase in the ability of the astrocyte to utilise 
glucose and produce pyruvate and lactate.  Measuring metabolic flux in co-
culture systems has specific challenges. There is a requirement to distinguish 
between neuronal and astrocytic metabolic changes. Furthermore metabolism 
can change rapidly in any cell in response to internal and external conditions. 
Hence any method must have appropriate spatial and temporal resolution to 
measure changes in metabolic flux in individual cells.  
To achieve the above, I utilised recently developed high resolution intracellular 
genetically-encoded florescent resonance-transfer (FRET) metabolic optical 
nanosensors, specific for glucose, pyruvate and lactate. FRET nanosensors have 
two fluorescence domains. Binding to a particular metabolic substrate results in 
a conformational change in the probe, resulting in energy transfer and an 
alteration in the ratio of emitted light from each of the two fluorescent domains. 
A measure of the ratio between the intensities within the two spectra 
corresponds to the intracellular concentration of the metabolic substance of 
interest. Plasmids for these sensors are transfected into astrocytes prior to co-
culturing with neurons, ensuring all metabolic measurements are specific for 
astrocytes. This cell-type specificity is also further confirmed by the 
morphological shape of transfected cells at the time of imaging.   
I used a glucose-specific-specific FRET nanosensor (FLII12Pglu-700uDelta6). 
The FRET ratio obtained gave me an indication of the concentration of glucose 
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present within the cell.  By inhibiting glucose uptake using the glucose 
transporter inhibitor cytochalasin B (CytoB), and by determining the rate of 
decline in intracellular glucose concentrations, I was able to measure the rate of 
glucose flux and the rate of utilisation via glycolysis (specifically the rate of 
conversion of glucose into glucose-6-phosphate by hexokinase). All imaging was 
done with astrocytes from both conditions perfused continuously with TTX, to 
ensure that any changes in metabolic activity found was as a result of exposure 
to prior neuronal activity. 
Mouse and human astrocytes co-cultured with active neurons (BiC) overnight 
demonstrated enhanced glucose utilisation vs those cocultured with silent 
neurons (TTX) (Figure 3.5 A, B, C). Furthermore, the effect on astrocyte 
metabolism appears to be long-lasting. Astrocytes exposed to high neuronal 
activity overnight, and then switched back into low-activity conditions, 
maintain an increased metabolic flux. This appears to slowly return back to 
baseline (Figure 3.5 D) and would fit with the prediction that observed 
metabolic changes are due to changes at the level of transcription and protein 
expression, leading to the long-lasting changes observed.  
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Figure 3.5 - Increased synaptic activity enhances astrocyte glucose utilisation.   A, B.  Mouse 
astrocytes exposed to high synaptic activity (BiC) vs low synaptic activity conditions (TTX) 
demonstrate increased rate of glucose utilisation following inhibition of glucose uptake with 
cytochalasin (TTX: n=14, BiC n=14, from 3 cultures ***p<0.001 unpaired t-test). C.  These findings 
are replicated in human astrocytes (TTX: n=16, BiC n=16, from 3 cultures *** p<0.001 unpaired 
t-test). D. Exposure to increased neuronal activity has long-lasting effects on astrocyte 
metabolism. Returning to low-activity conditions for >6h is still associated with increased rates 
glucose utilisation compared with astrocytes always kept in low-activity conditions (TTX: n=14, 
0 h: n=12, 2h: n=12, 6h n=14, cells from three cultures ***p<0.001, *p<0.05, unpaired t-test using 
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Glucose flux - following return from 
high to low activity.
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 Neuronal activity increases astrocyte lactate and pyruvate flux. 
 
To measure astrocyte lactate and pyruvate production, I utilised the Laconic and 
Pyronic FRET probes together with inhibition of lactate export using the lactate-
transporter blocker arc-C1558558 (AR-C). The subsequent rate of rise of 
intracellular lactate or pyruvate corresponds to a measure of the rate of 
production.  I found that exposure to increased neuronal activity leads to an 
increased pyruvate and lactate rate, consistent with the transcriptional changes 




Figure 3.6 - Increased synaptic activity enhances astrocyte 
pyruvate production. Mouse astrocytes are cocultured with rat 
neurons, and neuronal activity manipulated over night to create low 
(TTX) vs high (BiC) activity conditions. Pyruvate levels are measure 
using the Pyronic FRET sensors.  A. Samples traces demonstrating 
increased rate of pyruvate production in astrocytes exposed to high 
activity (Bic) conditions vs low activity (TTX). B. Pyruvate flux 
calculated as the rate of change of normalised Pyronic fret ratios after 
addition of MCT blocked with 1 μM arc-C1558558 (AR-C). High 
activity conditions lead to increased pyruvate production (TTX: n=41, 






























































































Figure 3.7 - Increased neuronal activity enhances astrocyte 
lactate production Similar to previous figures, mouse astrocytes are 
cocultured with rat neurons, and neuronal activity manipulated over 
night to create low (TTX) vs high (BiC) activity conditions. Lactate 
levels are measure using the Laconic FRET sensor.  A. Samples traces 
demonstrating increased rate of lactate production in astrocytes 
exposed to high activity (Bic) conditions vs low activity (TTX). B. 
Lactate flux calculated as the rate of change of normalised Laconic fret 
ratios after addition of MCT blocked with 1uM arc-C1558558 (AR-C). 
High activity conditions lead to increased lactate production (TTX: 
n=13, BiC: n= 12 cells from three cultures, *p <0.05- unpaired t-test, 































































































 Metabolic changes are driven via activation of the CREB 
pathway 
 Upregulated genes demonstrate enrichment for the CREB promoter motif 
 
I next set out to determine the intracellular signalling pathways by which 
neuronal activity drives the above alterations in astrocyte metabolism. A 
promoter analysis of genes induced more than twofold by both BiC and 
BiC+TBOA found the highest enrichment was for members of the cAMP 
response element binding protein (CREB) family. CREB family transcription 
factors are responsive to both Ca2+ and cAMP/PKA signalling (Figure 3.8). The 
role of the CREB pathway has been well described in neurons, where it is 
important for learning and memory (Benito et al., 2010). However, its role in 





Figure 3.8 - Promoter analysis of activity-regulated genes reveals 
enrichment for the CREB promoter motif. A. Promoters of astrocytic 
activity-responsive genes (induced more than twofold) were analysed within 
Genomatix for enrichment in TRANSFAC Library matrices, with the Z-score for 
enrichment calculated. The CREB family matrix is the most enriched and is 
highlighted. B.  Example of the CREB signalling pathway. Extra-cellular signals 
are transduced via a transmembrane receptor, resulting in second-messenger 
production of cAMP. These then activate protein kinases (PK) by causing 
dissociation of PK-dimers. The activated PK translocates to the cell nucleus and 
phosphorylates CREB-protein. This activates the CREB transcription factor, 
allowing it to bind to CRE-response elements via its basic leucine-zipper 
domain, and initiating transcription of down-stream genes.  
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 CREB activation is sufficient and necessary to drive activity-dependent 
metabolic changes. 
 
To test whether CREB signalling was sufficient to enhance astrocyte glucose 
flux, I transfected astrocytes with a constitutively-expressed variant of CREB 
(VP16-CREB, formed by fusing CREB with the Herpes Simplex virus protein 
VP16). I found that constitutively driving CREB was sufficient to increase 
astrocyte glucose utilisation and lactate production even when neurons were 
kept in low-activity (TTX) conditions. I then inhibited CREB by transfecting 
astrocytes with the Inducible cAMP Early Repressor (ICER) protein. This is an 
endogenous inhibitor of the CREB pathway (Jaworski et al., 2018). Co-
transfection of astrocytes with the CREB inhibitor ICER, was able to reverse 
activity-dependent changes in astrocyte glucose metabolism in both mouse and 
human astrocytes (Figure 3.9). These data suggest that the CREB-activation is 
sufficient and necessary in mediating neuronal-activity mediated changes to 


































































































































































































Figure 3.9 - CREB activation is sufficient and necessary to drive synaptic-activity 
mediated changes in astrocyte metabolism.  A, B. Expression of constitutively-
expressed CREB (VP16-CREB) is sufficient to enhance glucose utilisation (globin: n=36 
globin, VP16-CREB: n=29, cells from three cultures *** p <0.001 unpaired t-test) and 
lactate production (globin: n=47, VP16-CREB: n=30, cells from three cultures ***p < 
0.001 unpaired t-test, using cells as replicates) in co-cultured astrocytes kept in low-
activity conditions (TTX). C, D.  Activity-mediated changes in astrocyte glucose 
metabolism are reversed by co-transfecting cells with the CREB inhibitor ICER in mouse 
and human cells. (TTX globin: n=33, BiC globin: n= 26, TTX ICER: n=10, BiC-ICER: n=13, 
cells from 3 cultures; ***p<0.001 compared to TTX or Bic + ICER, 2-way ANOVA with 
Sidak’s multiple comparisons, using cells as replicates).  
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 Drugs promoting upstream CREB activity boost astrocyte metabolic flux. 
 
Having elucidated a key role for the CREB-signalling pathway in driving 
neuronal activity mediated changes to astrocyte transcription and metabolism, 
I was next interested in whether drugs acting upstream off CREB could also 
increase astrocyte metabolic flux. I found that the cAMP activator forskolin 
potently enhanced metabolic gene-expression along with glucose flux. In 
addition, other drugs that act on the cAMP pathway such as the  
phosphodiesterase inhibitors 3-isobutyl-1-methylxanthine (IBMX) and the  
PDE type-3 specific inhibitor cilostazol, as well as Gs activators (noradrenaline) 
increased astrocyte metabolic flux (Figure 3.10 B). Finally, I confirmed that the 
action of forskolin in boosting astrocyte metabolism was through activation of 
CREB, by confirming that any increase in metabolic flux could be reversed by 
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Figure 3.10 - Drugs acting upstream of CREB by elevating cAMP levels enhance 
astrocyte metabolic flux. A. Treatment of cocultured astrocytes with the adenylate-cylase 
activator forskolin (Fsk) increases astrocyte metabolic gene expression. Mixed rat 
neuron/mouse astrocytes were treated with forskolin (10 μM for 16 h) and gene 
expression measured by qPCR using mouse-specific primers. (N=3, *P<0.05 (2-way ANOVA 
plus Sidak’s method for multiple comparisons). B. cAMP boosting drugs enhance astrocyte 
metabolic flux. 10 μM forskolin (cAMP activator) treatment and 2 μM cilostazol (PDE3 
inhibitor) boost astrocyte glucose utilisation (n= 29 DMSO, n=25 forskolin(Fsk), n = 25 
cilostazol (Cilas), 2 cultures ***= p<0.001, 1-way ANOVA with Sidak’s multiple 
comparisons, using cells as replicates). C. Forskolin mediated increases in astrocyte 
metabolism occur via the CREB pathway. Co-expression of the CREB inhibitor ICER 
reverses forskolin mediated increase in glucose flux. (n= 11 DMSO, n=14 Fsk, n= 11 
Fsk+ICER , cells from two cultures ** p <0.01, ***p<0.001, 1-way ANOVA plus Sidak’s 
multiple comparisons, using cells as replicates).   
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 Chapter Discussion 
 Summary of findings 
The data presented in this chapter demonstrate that neurons induce 
transcriptomic and functional changes in astrocytes. I first extended and 
confirmed previous transcriptomic findings from our lab in human astrocytes. I 
next went on to confirm that activity-induced transcriptomic changes translated 
into activity-induced metabolic changes in astrocytes. Neuronal activity 
increases astrocyte glucose uptake and lactate production. Finally, I 
demonstrated that activity-induced changes occur via activation of the astrocyte 
CREB pathway, and can be enhanced by drugs acting upstream of CREB.  
 Conservation between rodent and human astrocytes 
Prior work in our lab elucidated that coculture with mouse neurons, as well as 
altered synaptic activity, altered gene expression in mouse astrocytes. However, 
there are significant inter-species differences between human and rodent 
astrocytes. Human astrocytes are larger and more complex, making contact with 
a greater number of synapses (Oberheim et al., 2009, Han et al., 2013). 
Compared with other CNS cell-types, marked differences in gene-expression 
have also been found between murine and human astrocytes (Zhang et al., 
2016).  Therefore, it was important to check to what extent the neuron-
astrocyte signalling pathways that we were investigating were conserved 
between rodents and humans to provide confidence that any further 
 95 
investigations using rodent models would be applicable to human physiology 
and disease.  
The data presented above demonstrate that human astrocytes undergo similar 
morphological changes in response to neurons. They also demonstrate 
conservation with rodent astrocytes in their transcriptional response to neurons 
and synaptic activity, and in the manner in which synaptic activity regulates 
metabolic flux.   
An important limitation with the above data is that utilisation of only a small 
selection of genes from the rodent datasets. This approach is biased and may 
miss pathways that are differentially regulated between species. An unbiased 
panel of genes that are upregulated, down-regulated and not changed (or 
utilising RNA-sequencing) would allow us to investigate the true extent of 
conservation between humans and mouse astrocytes.  
However, with the above limitation considered, the overall conservation of both 
contact-mediated and activity-dependent functional responses suggest that 
there is evolutionary conservation in these selected key pathways between 
human and rodent astrocytes, thus providing confidence in the translatability 




 Consequences of activity-dependent regulation of astrocyte 
metabolism. 
The main finding described in this chapter was that synaptic activity drives 
long-lasting transcriptional changes in astrocyte metabolic flux. This has 
important implications for how neuron-astrocyte signalling regulates metabolic 
homoeostasis in the CNS.  Astrocytes are the largest uptakers of glucose in the 
CNS during periods of strong synaptic activity (Zimmer et al., 2017). According 
to the ANLS hypothesis, synaptic activity leads to glutamate uptake and 
glutamine synthesis in astrocytes. This in turn, by the laws of mass-action, 
triggers increased lactate export from astrocytes (Pellerin and Magistretti, 
1994b). This lactate can then serve as an important fuel source for nearby 
neurons. 
The data presented in this chapter reveal that synaptic activity regulates 
transcription to drive an enhanced capacity of an astrocyte to utilise glucose and 
produce lactate. This ensures that the ability of the astrocyte to supply 
metabolic substrates is tuned to the neuronal activity of nearby neurons, hence 
ensuring that metabolic supply meets metabolic demand in the CNS. This 
reveals a novel pathway by which synaptic activity tunes astrocyte transcription 
to regulate metabolic homeostasis in the neuroglial unit. 
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 Utilising the CREB pathway for future therapeutic use. 
I also describe the role of the CREB signalling pathway, demonstrating that 
CREB activation was sufficient and necessary for mediating activity-dependent 
astrocyte transcriptional and metabolic changes. CREB has previously been 
demonstrated to have important roles in mediating activity-dependent 
neuroprotection in neurons (Shaywitz and Greenberg, 1999). Its role in 
astrocytes is much well less understood, although recently it has been 
demonstrated that CREB activation in astrocytes leads to the activation of 
distinct transcriptional programmes different from those seen in neurons 
(Pardo et al., 2017). Activation of CREB in astrocytes also has a neuroprotective 
role and has been shown to reduce injury in a stroke model (Pardo et al., 2016).  
Consistent with its role in mediating activity-dependent transcriptional and 
metabolic changes, targeting the CREB pathway boosts astrocyte metabolic flux.  
This offers a potential drug target that might be of future therapeutic benefit. 
Interestingly, phosphodiesterase (PDE) drugs that target the cAMP and CREB 
pathways (e.g. rolipram, a Type 4 PDE and cilostazol, a Type 3 PDE) have 
already been trialled in neurodegenerative conditions. Whilst their actions on 
astrocytes have not been considered, it may be that some of their consequences 
on CNS health may come from effects via activation of astrocyte pathways. This 
is discussed further in chapter 6.  
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 The role of other transcriptional pathways altered by neuronal 
activity. 
In this chapter, I have focused on the consequences of neuronal activity on one 
pathway uncovered by transcriptional data – that of astrocyte metabolic flux. 
However other notable gene clusters identified include those involved in 
thyroid hormone signalling (Slco1c1, Dio2 and Slc7a5) and antioxidant capacity 
(Sod3 and Grx3). These suggest that synapse-astrocyte signalling is also 
essential for regulating other key trophic and protective pathways in the brain, 
and investigating the functional consequences of these pathways, and whether 
they are disrupted in neurodegeneration, offers an interesting avenue for future 
investigation.  
 
 Limitations and future work. 
The main limitation of these studies is that they are carried out in a mixed-
species coculture system. Astrocytes grown in culture are different from those 
found in vivo (Cahoy et al., 2008). Whilst we have discovered that coculturing 
astrocytes with neurons does push astrocytes somewhat towards a more in vivo 
state, differences still exist.  Furthermore, our co-culture system lacks other 
important cell types such as oligodendrocytes, microglia or vascular cells. 
Interactions with these cells may alter astrocyte gene-expression and function 
further. I address these limitations in the next experimental chapter.  
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It is also important to consider artefacts that may be induced by mixing cells 
from different species.  Mouse and rats CNS cells demonstrate a high level of 
evolutionary conservation, and similarities in transcription and functional 
changes between human and rodent astrocytes further support the high level of 
conservation in these important pathways. Furthermore, astrocyte genes that 
could be tracked in single-species co-culture (due to being >10 fold expressed 
in astrocytes vs other cell-types) which changed with rat neurons were also 
significantly changed in mouse-astrocytes cultured with mouse neurons (Hasel 
et al., 2017 - Supplementary Table 5), again supporting that neuron-astrocyte 
signalling pathways demonstrate a high-level of conservation between rat and 
mouse.  However, whilst this increases confidence that the findings in this 
chapter are applicable in normal physiology, there will nevertheless be 
differences that will influence some aspect of transcription and function. 
Therefore, there is a requirement to test and confirm these findings in a more 
complicated in-vivo system. These investigations are described in the next 
chapter. 
 
 Chapter conclusion 
The studies in this chapter demonstrate how synaptic activity alters astrocyte 
transcription to drive long-lasting enhancement of pathways for astrocyte–
neuron metabolic support. Activity-dependent changes occur via activation of 
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the CREB transcription factor, and astrocyte metabolic flux can be enhanced in 







In vivo consequences of 




 Chapter Introduction 
In the previous chapter, I described investigations seeking to understand how 
synaptic activity regulates astrocyte gene-expression using an in vitro co-culture 
model. These revealed that synaptic activity led to widespread transcriptomic 
changes in astrocytes. However, given the caveats with using cultured cells 
(discussed previously), it was important to confirm to what extent synaptic 
activity regulated astrocyte transcription in vivo.  
To answer this question, I was required to overcome two separate 
methodological challenges. First, I had to distinguish astrocyte-specific gene-
expression changes from those in other CNS cell-types. Second, I had to 
determine a paradigm for generating conditions of high vs low neuronal activity 
in vivo.  
With regards to separating astrocyte vs other CNS cell-type transcription: in 
vitro, we utilised mixed-species coculture and exploited inter-species 
differences in genetic sequence to separate cell-type specific reads post-
sequencing.  However, in vivo this approach would not be possible.  
Current methods for achieving cell-type specific gene expression include: 1) 
Florescence-assisted cell sorting (FACS), 2) Magnetic sorting 3) Single-cell RNA 
sequencing. Whilst these are all powerful tools that allow physical separation of 
cells prior to RNA-sequencing, they have important caveats. Firstly they require 
tissue homogenisation and cell-dissociation into a single cell suspension prior 
to separation. This homogenisation can induce transcriptional changes that 
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may mask any activity-induced effects (Liu, Morgan and Pine, 2014). Secondly 
the time-delay between homogenisation and RNA-sequencing when the cell is 
still alive can further influence transcriptional changes. Astrocytes, being highly 
reactive cells with multiple fine processes, are particularly prone to damage and 
artefact following sorting.  
For these reasons, I decided to utilise an alternative technique: translating 
ribosome affinity purification (TRAP - Figure 4.1). In TRAP, cell-type specific 
expression of GFP-tagged ribosomes is driven by a cell-type specific promoter. 
Immunoprecipitation of GFP-tagged ribosomes allows isolation of attached cell-
type specific mRNA.  In the first part of this chapter I describe validation and 
optimisation of the TRAP methodology to successfully allow measurement of 
astrocyte-specific transcriptional changes. 
TRAP has benefits over the other methods described above. First, it does not 
require tissue dissociation into a single-cell suspension prior to RNA collection. 
Instead, dissected tissue is rapidly homogenised in buffer containing 
cyclohexamide which fixes the ribosome-mRNA complexes. Hence, the 
transcriptional state of the cell is preserved to the time the animal is culled, 
minimising transcriptional artefacts induced by tissue dissociation and delay.  
Second, TRAP isolates actively translating mRNA. Therefore any changes found 
in gene-expression may better reflect functionally relevant pathways than those 











Figure 4.1 - Schematic of translating ribosome affinity purification 
(TRAP) method.  Tissue from the astro-TRAP mice brains are lysed 
and incubated (in the presence of RNAse and proteinase inhibitors) 
overnight with anti-GFP coated beads. The beads bind to the EGFP-
tagged rpl10a protein of the 60S unit of the ribosome. This pulls down 
ribosomal complexes along with translating mRNA. An input sample 
taken prior to IP contains mRNA from all cell-types.  
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The second challenge was to develop a suitable paradigm to manipulate 
synaptic activity in vivo. In the second part of this chapter I describe optimising 
a light-stimulus paradigm to achieve conditions of high vs low neuronal activity 
in the visual cortex. By combining light-stimulus along with astrocyte-specific 
TRAP, I was able to investigate how altered synaptic activity controls astrocyte 
gene-expression in vivo.  
In the final part of the chapter, I explore the consequences on CNS transcription 
in a clinically relevant model where synaptic activity is suppressed: prolonged 
anaesthesia. I describe how anaesthesia suppresses activity-dependent neuronal 
and astrocyte gene-expression, and investigate the functional consequences of 
these transcriptional changes on pro-survival and death pathways in the CNS.  
Finally, I demonstrate that anaesthesia-induced transcriptional changes during 
anaesthesia might be reversed when synaptic activity is upregulated using non-




 Validation of Aldh1l1-EGFP-Rpl10a transgenic mouse line 
Cell-type specificity of TRAP is achieved by driving EGFP expression under a 
cell-type specific promoter. We utilised a transgenic mouse (Aldh1l1-EGFP-
Rpl10a - referred to in this thesis as the astro-TRAP mouse) where EGFP is 
driven under the expression of the Aldh1l1 gene promoter.  Aldh1l1 is expressed 
specifically in astrocytes in the CNS (Figure 4.2A) and is generally considered 
as being the archetypical astrocyte marker, demonstrating the best sensitivity 
and specificity for astrocytes compared to alternative astrocyte markers or 
promoters such as Gfap, S100B and Slc1a3 (Srinivasan et al., 2016).  The 
transgenic mouse had already been previously generated and described 
(Heiman et al., 2008) and the line was re-derived from frozen sperm on a 
C57B/6JN background as outlined in methods.  
To confirm that EGFP was correctly expressed only in astrocytes in the re-
derived line, I took slices of cortex from 8 week old astro-TRAP mice and co-
stained with anti-EGFP and either anti-ALDH1L1 or a pan-neuronal antibody 
(Neurochrom) (Figure 4.2B). Confocal imaging of the cortex using coronal 
sections demonstrated that EGFP staining was present only in astrocytes (as 
confirmed by both morphology and anti-ALDH1L1 costaining), and not present 
in neurons.   
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To further validate the identity of EGFP expressing cells, I isolated EGFP+ cells 
using fluorescence-activated cell sorting (FACS). The gene-expression profile in 
eGFP+ vs GFP- cells was determined by qPCR with a panel of cell-type specific 
gene-markers. These markers were selected from Ye Zhang et al., 2014, as genes 
that demonstrated >10 fold specific expression in an individual cell-type vs 
expression in other cell-types. EGFP+ cells showed enrichment for astrocyte-
specific genes, and depletion of neuronal, oligodendrocyte and microglial genes 





































































































Figure 4.2 - Validating astrocyte-specific GFP expression in the Alh1l1-egfp-rpl10a 
transgenic mouse. A. Aldh1l1 is an astrocyte-specific marker, demonstrating enrichment in 
astrocytes vs other CNS cell-types. Data taken from Ye Zhang et al., 2014.  B. C. Confocal 
images, along with quantification of cell counts, confirms EGFP is selectively expressed along 
with Aldh1l1 (mean ± SD, N=4) in astro-TRAP mice. Neurons, labelled with the polyclonal pan-
neuronal marker Neurochrom, do not exhibit EGFP expression. D. Separation of EGFP + cells 
by flow-cytometry and assessment of cell-type specific genes by qPCR confirms enrichment of 
astrocyte-specific markers (Aldh1l1, Gfap, Slc1a3) and depletion of markers for other cell-types 
(Tubb3, Mog, Aif1). (N = 3, **p<0.01 – 1 way ANOVA on each gene-set).  
 109 
 Optimisation of TRAP protocol to obtain cell-type specific mRNA 
Having successfully confirmed that astro-TRAP transgenic mouse expressed 
EGFP in an astrocyte-specific manner, I next set out to validate and optimise a 
protocol for isolating astrocyte-specific mRNA by immunoprecipitation. This 
involved modifying previously published methodology (Heiman et al., 2014) 
until satisfactory enrichment of astrocyte vs other CNS cell-types genes was 
achieved.   
I first determined the optimal ratio of anti-GFP coated beads to tissue to 
determine the optimal balance between maximising mRNA yield and 
minimising background contamination.  I carried out immunoprecipations 
using different amounts of mouse cortex and assessed RNA yields and quality 
using an Agilent bioanalyser. To determine the amount of background mRNA 
contamination that was not reliant on EGFP-pulldown and to confirm that the 
above enrichment was indeed due to the expected mechanism of EGFP-specific 
ribosome pulldown, the TRAP method was repeated with two specific controls. 
Firstly, immunoprecipation was performed on brain samples from wild-type 
mice.  Second, immunoprecipitation was performed on astro-TRAP mice, with 
substitution of the anti-EGFP antibodies with a control antibody (anti-myc). In 
both controls, neglible RNA amounts were obtained following TRAP. This 
demonstrates that the mechanism of RNA pulldown required IP of GFP-tagged 
ribosomes, and confirmed that there was minimal background mRNA 




Table 4-1: RNA extraction requires anti-GFP binding to 
GFP-tagged ribosomes.  Post-TRAP RNA yields only 
significant in Astro-TRAP mice with anti-GFP antibodies, and 
negligent with wt mice or using control (c-myc) antibody. 
(N=2, mean (±SD)). 











59.4 (±5.4) 70.6 (±7.35) 53 (±3.4) 
POST-TRAP 
CONCENTRATION 
(NG/ ΜL ) 
28.5 (±1.5) 1.5(±0.45) 1.2 (±0.64) 
 
I next checked if the RNA obtained by TRAP demonstrated successful 
enrichment of astrocyte vs other cell-types genes. This was done by comparing 
the expression of cell-type specific gene markers from the TRAP samples vs the 
input samples. Cell-type specific markers were identified as genes from the Ye 
Zhang et al., 2014 dataset that were >10 fold enriched in a particular cell-type 
vs other cell-types. TRAP successfully enriched for astrocyte-specific markers 
and depleted for markers from other cell-types (Figure 4.3A).  
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Finally, I confirmed that there was minimal background contamination by 
looking for depletion of mitochondrial mRNA. Mitochondrial mRNA is 
translated by mitochondrial ribosomes rather than cytoplasmic ribosomes 
(Greber and Ban, 2016). As mitochondrial ribosomes in the astro-TRAP mice 
are not EGFP-tagged, mitochondrial RNA would not be expected to be isolated 
by TRAP. Hence it serves as a useful marker for determining the success of the 
TRAP method and assessing the level of background RNA contamination. I 
found that TRAP samples demonstrated a strong reduction of all mitochondrial 
genes compared to input samples following RNA-sequencing (Figure 4.3B).   
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* * * * * *


























































































































Figure 4.3 - TRAP allows isolation of cell-type specific mRNA from whole brain. A. 
TRAP successfully allows isolation of astrocyte-specific mRNA from cortical samples, 
confirmed by enrichment of astrocyte-specific genes and depletion of markers of other 
cell-types (N=4, *** p<0.001, 1-way ANOVA on each gene-set).  B. TRAP samples have a 
strong depletion in mitochondrial mRNA (translated by non-GFP tagged mito-
ribosomes) vs input samples (N=4, *** p<0.001, 1-way ANOVA).  
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 Using light-stimulus to manipulate synaptic activity in vivo. 
Having selected and confirmed TRAP as a suitable method for measuring 
astrocyte-specific transcription in vivo, I next required to establish paradigms by 
which I manipulate synaptic activity upwards and downwards. In cell culture, 
we utilised drugs (bicuculline and TTX) to achieve high vs low neuronal activity 
states. However, these cannot be used in vivo as they would result in animal 
death.  
It was important for any suitable paradigm to be as non-invasive as possible. 
This was both for animal welfare purposes and to minimise changes in gene-
expression due to injury or CNS trauma that may occur with invasive methods. 
Astrocytes are very reactive and alter their gene-expression profile rapidly to 
injury. This would mask transcriptional changes resulting from altered neuronal 
activity.  
For these reasons, I decided to utilise a light-stimulus paradigm to manipulate 
neuronal activity in vivo. This exploits the fact that the primary visual cortex 
(V1) is innervated mainly from the retina by a neuronal circuit through the 
lateral geniculate nucleus (Figure 4.4B). Exposing mice to light vs darkness 
creates conditions of high vs low neuronal activity in the V1 visual cortex. The 
visual cortex does receive input from other cortical areas (Macaluso, Frith and 
Driver, 2000). Whilst this means that in darkness there would not be the total 
absence of synaptic activity, we predicted that exposure to light vs darkness 
would lead to a sufficient difference in synaptic activity to drive changes to 
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astrocyte transcription.  This method has been extensively described previously 
as a method to achieve altered neuronal activity, and well established to alter 
activity-dependent transcription in the visual cortex (Majdan and Shatz, 2006). 
Benefits of this method were that it was easy to implement and non-invasive, 
thereby minimising non-specific gene-expression effects.  
Mice were first kept in total darkness for 7 d. A period of 3- 14 days of darkness 
prior to light-exposure is consistently used in studies employing light-stimulus 
(Ataman et al., 2016, Hrvatin et al., 2018, Murase, Lantz and Quinlan, 2017) as 
a means to achieve a low baseline on which to measure subsequent effects of 
light-stimulation. Following 7 d dark exposure, mice were then exposed to 
different periods of light (4 h – 48 h). Visual cortices were then dissected and 
gene-expression measured by RNA extraction and qPCR.  
Changes in neuronal activity was confirmed by measuring expression of two 
immediate-early genes (IEGs) Arc and Bdnf. These genes were selected as 
established activity dependent markers that have been previously described to 
respond robustly to increased neuronal activity (West and Greenberg, 2011). I 
determined that light stimulus upregulates neuronal activity in the visual cortex 
and that the optimum time-point when there was greatest upregulation 
appeared to be 24 h of light-exposure (Figure 4.4C). Finally, I also checked the 
expression of these genes in mice kept in a normal light-dark cycle (Normal 
light). These consistently appear to have higher levels of IEG gene expression 
compared to mice exposed to darkness for 7 d.  
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Using the 24 h light-stimulus time-point, I next investigated if there was 
difference between younger (post-natal day 28) and older (24 week old) mice. I 
predicted that older mice would have reduced plasticity in their visual cortices, 
and therefore demonstrate reduced change in gene-expression in response to 
light-stimulus compared to younger mice. However, I found no difference 






Figure 4.4 - Light stimulation allows regulation of neuronal activity. A. Schematic of 
stimulation paradigm. Mice were exposed to continuous darkness for 7d followed by either being 
kept in darkness, or variable period of light exposure. B. Visual cortex is innervated by a neuronal 
pathway from the retina. Hence, light vs dark exposure creates conditions of high vs low synaptic 
activity. C. Light exposure increases expression of immediate-early genes Arc and Bdnf (dark: N=6, 
24h light: N =6, 48h light: N=3; Normal light: N=4.  *p<0.05, **p<0.01, ***p<0.001 compared to 
dark, 2-way ANOVA with Sidak’s multiple testing,). D. Light-induced changes in Arc and Bdnf 
expression are similar between old and young mice (4 week old mice: N=5; 24 week old mice: N 
















































































































 Neuronal activity alters astrocyte transcription in vivo. 
 
Combining the above two approaches, I next investigated how synaptic activity 
altered astrocyte transcription in vivo.   This was done by exposing astro-TRAP 
mice to 24 h light v dark stimulus, and subsequently isolating astrocyte-specific 
mRNA using TRAP. P28 astro-TRAP mice were kept in 7 days of complete 
darkness and then either exposed to 24 h light or a further 24 h of darkness. In 
addition a control group were kept in normal light-cycle conditions. RNA-seq 
of TRAP mRNA isolated from the visual cortex revealed that 24 h light alters a 
wide-programme of astrocyte gene-expression (Figure 4.5A). Furthermore a 
larger number of genes were found to be altered in mice kept in normal light 
































































Figure 4.5 - Light-stimulus alters a wide-programme of astrocyte gene 
expression. A. Astrocyte gene expression measure by TRAP and compared between 
mice kept in darkness and mice exposed to 24 h light. A large number of genes have 
significantly altered gene-expression (Red – genes upregulated >1.3 fold, p_adjusted 
< 0.05, Blue - genes downregulated >1.3 fold, p_adj <0.05, N=4 mice in each condition) 
B. Similar to above, but utilising mice exposed to normal light-dark cycle vs those kept 
in darkness (N=4 mice in each condition).  
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 In vivo transcriptional changes correlate with in vitro changes 
 
I next investigated whether the astrocyte transcriptional changes seen with light 
stimulus correlated with our previous in vitro transcriptomic findings. 
Comparisons were done using both 24 h light vs dark (Figure 4.6A, B) and 
normal light vs dark (Figure 4.6 C, D) transcriptomic changes. These were 
compared to changes seen in astrocytes in cocultures exposed to 24 h of 
bicuculline or bicuculline+TBOA, vs TTX, to increase synaptic activity. 
I found that in vivo transcriptomic changes broadly overlapped and correlated 
well with gene-sets regulated by altered synaptic activity in vivo, with slightly 
stronger correlations between genes changed with 24h light vs dark than those 
changed with normal light vs dark.   
Activity-dependent astrocyte genes identified in our experiment were also 
compared to other recently published datasets (Figure 4.7). We found activity-
dependent astrocyte genes identified from the above study overlapped with 
astrocyte genes identified in a recent publication utilising a light-stimulus 
paradigm of 1 h or 4 h light with single-cell sequencing of the visual cortex 
(Hrvatin et al., 2018).  Activity-dependent astrocyte genes also overlapped with 
those that are regulated during sleep (Bellesi et al., 2015). Finally, utilising data 
from a study examining astrocyte gene-expression in aged (2 y) vs adult mice (4 
month old) (Boisvert et al., 2018), we found that activity-dependent genes are 
significantly down-regulated with ageing.  
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Figure 4.6 - Astrocyte genes regulated by light stimulus overlap with genes 
regulated by neuronal activity in vitro. A.  Changes in astrocyte gene-expression 
following 24h light-stimulus vs dark or normal light exposure vs dark correlate to 
changes seen in astrocyte gene-expression in vitro. (N=4 mice or cultures, 
Spearman’s rank correlation). B. Overlap between genes changing in vitro (Bic vs 
TTX, or Bic vs TTX with the addition of TBOA) vs genes upregulated (red) or 
downregulated (blue) with 24 h light stimulus vs dark.  Percent overlap is fraction 
of genes from each gene-set that are significantly up or down-regulated , n = total 
number of genes in each set (***p<0.001, Fisher’s exact test) C, D. Similar to above, 
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Figure 4.7 - Investigating overlap of activity-dependent astrocyte genes with 
datasets from other studies.  Changes in astrocyte gene expression between mice 
kept in normal light vs those in dark were compared to published datasets. There 
was strong overlap found in gene-sets between astrocyte genes changes with 1 and 
4 hr light stimulus isolated by single-cell sequencing (#Hrvatin et al., 2018), and 
with genes that were increased in awake and sleep-deprived mice vs asleep mice 
(##Bellesi et al., 2015), and astrocyte genes that are downregulated in aged (2y old) 
vs adult (8 week old) mice (###Boisvert et al., 2018). Percent overlap is fraction of 
genes from each gene-set that are significantly up or down-regulated , n = total 
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 Comparing activity-dependent transcription with activity-
dependent translation. 
Gene expression is a multistep process involving transcription of DNA to 
produce mRNA, and then subsequent translation of mRNA into protein. 
Transcriptional levels of mRNA may not correlate with protein levels. Post-
transcriptional modification regulates mRNA translation and protein levels are 
also controlled by degradation.  Whilst total mRNA levels correlate poorly with 
cellular protein levels, the cellular abundance of proteins is predominantly 
controlled at the level of translation (Schwanhäusser et al., 2011).  
Normal RNA isolation methods purifies all mRNA in the cell, whilst the mRNA 
isolated using TRAP is that which is being actively translated. Whilst we found 
a large overlap between gene-sets changed by neuronal activity in vivo (light vs 
dark) with those changed in cell-culture (Bic vs TTX), there were some genes 
that were differentially regulated. These differences could be due to the 
differences between neuron-astrocyte interactions in vitro vs in vivo, or might 
represent a difference between total transcribed mRNA and translated mRNA.  
I therefore set out to investigate to what extent neuronal contact and synaptic 
activity effected astrocyte gene-transcription vs gene-translation. I did this by 
developing a novel method employing a combination of the mixed-species 
coculture methodology along with TRAP. By coculturing astro-TRAP astrocytes 
with rat neurons, and by sequencing both the input (total transcribed mRNA) 
vs that obtained by ribosomal pull-down (translating mRNA), I could 
 123 
distinguish astrocyte-specific transcribed and translated mRNA. Furthermore 
the use of the species-specific sorting algorithm allowed me to distinguish and 
remove the rat neuronal reads from mouse astrocyte reads in both total mRNA 
(transcribed) and TRAP mRNA (translated).  Hence, this approach allowed the 
investigation of non-cell autonomous effects of neurons and neuronal activity 
on astrocyte transcription vs translation.  
I discovered a very strong correlation between astrocyte genes that are altered 
at the level of transcription with their subsequent change at the level of 
translation in response to both neuronal contact and synaptic activity (Figure 
4.8 A, B). The correlation was stronger with activity-dependent changes, vs 
contact dependent changes.  
We next investigated whether any genes demonstrated significantly different 
regulation between transcription and translation levels. This was done by 
building a statistical model that included the interaction between input 
(transcribed mRNA) vs TRAP (translating mRNA) into the Deseq2 statistical 
framework. This approach revealed a large number of astrocyte genes exhibiting 
a statistically different change (Deseq2 p_adj < 0.05, n= 345) between 
transcriptional and translational change in response to neuronal contact 
(Figure 4.8 C, D).  In contrast, very few genes appear to be differentially 
regulated between transcription and translation in response to altered neuronal 
activity (Deseq2 p_adj <0.05, N = 8). Furthermore, some of the activity-induced 
astrocyte genes in this group, whilst demonstrating statistical significance in 
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difference between transcriptional vs translational change, the overall fold-
change is very small. Hence the difference in these genes is unlikely to be 
biologically important.  
Gene ontology analysis of the genes differentially regulated at the level of 
transcription and translation in response to neuronal contact revealed 
enrichment for pathways related to astrocyte oxidative phosphorylation and 
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Figure 4.8 - Combining TRAP with mixed-species coculture to investigate changes in 
astrocyte transcription vs translation. A. Astro-TRAP astrocytes were cocultured with rat 
neurons for 9 days or maintained as monoculture. Total mRNA was extracted and TRAP utilised 
to investigate only translating mRNA. The fold change in total mRNA levels (transcribed gene-
expression) correlates well with TRAP mRNA levels (translated gene expression). B. Astro-TRAP 
astrocytes cocultured with neurons were exposed to high vs low activity conditons (24h of Bic vs 
Bic+TTX). Transcriptional vs translational change in gene-expression determined as above. C.D. 
Only genes that exhibit a significant difference between transcriptional and translational fold 
change (Deseq2 p_adj<0.05) are shown. Changes to astrocyte gene-expression in response to 
neuronal contact appear to show a greater degree of post-transcriptional control than changes in 
astrocyte gene-expression in response to altered synaptic activity.  E. Panther over-
representation pathway analysis of astrocyte genes that are differentially regulated at the level of 
translation vs transcription in response to neuronal coculture reveals upregulation of pathways 




 Prolonged anaesthesia suppresses neuronal and astrocyte 
transcription. 
Having determined that synaptic activity in vivo altered astrocyte transcription, 
I next set out to investigate if a more clinically relevant paradigm associated 
with reduced neuronal activity - that of prolonged sedative anaesthesia – also 
had consequences on CNS transcription. Anaesthetics are well established to be 
potent suppressors of neuronal activity. They are typically GABA receptor 
agonists or NMDA receptor antagonists (Franks and Lieb, 1994), and suppress 
neuronal firing (Ries and Puil, 1993), inducing burst suppression on EEG 
(Lukatch, Kiddoo and MacIver, 2005).  
In clinical studies, anaesthesia has been implicated in increasing perioperative 
delirium, memory impairment and longer-term cognitive impairment in 
humans and animals (Dutton et al., 2002; Culley et al., 2004; Bratzke et al., 
2018). However the pathways by which anaesthesia drives these long-term 
effects is unclear. Furthermore many previous studies have focused on neuronal 
consequences, with the effects of anaesthesia on glia being less well understood.  
To investigate whether anaesthesia alters CNS and astrocyte transcription, I 
exposed mice to 6 h anaesthesia using the volatile anaesthetic agent isoflurane. 
Animals were monitored throughout to ensure adequate oxygenation, 
temperature and hydration. Following the anaesthetic period, RNA was 
extracted from the cortex and analysed by RNA sequencing. By anaesthetising 
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astro-TRAP mice, I was able to use TRAP to investigate effects of anaesthesia on 
astrocyte vs other CNS cell-type gene expression.  
6 h isoflurane anaesthesia has a profound effect on total CNS gene expression 
(Figure 4.9A), altering the expression of thousands of genes.  Confirming its 
action as a potent suppressor of neuronal activity, anaesthesia suppresses a large 
number of known immediate-early genes and activity-dependent CNS genes 
(Figure 4.9B).  
Anaesthesia also influences a wide-programme of astrocyte gene expression, 
(Figure 4.10A). Genes that were significantly changed by both anaesthesia and 
dark-exposure demonstrated a very good correlation in induction and overall 
direction of change.  Interestingly, both activity-dependent and activity-
independent populations of genes altered by anaesthesia were identified 
(Figure 4.10C). Some activity-dependent upregulated astrocyte genes that 
would be expected to be suppressed by anaesthesia were upregulated – 
demonstrating there is a complex astrocyte response to the anaesthetic insult, 































































































1.3 fold and p_adj < 0.05
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Figure 4.9 - Prolonged anaesthesia alters CNS gene expression. A. RNA-
sequencing of brains exposed to 6 h isoflurane anaesthesia vs awake mice 
demonstrates that anaesthesia induces a change in a large number of genes 
(Red – genes upregulated >1.3 fold, p_adj<0.05, Blue-  genes downregulated 
>1.3 fold, p_adj <0.05, N=5 mice awake vs anaesthetised). B. Anaesthesia 
reduces expression of activity-dependent immediate early genes (N=5, 
p<0.001, 1-way ANOVA).  
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Figure 4.10 - Prolonged anaesthesia alters astrocyte transcription, with 
correlation with genes driven by synaptic activity. A. TRAP-seq used to measure 
astrocyte-specific transcriptomic changes in mice undergoing 6h isoflurane 
anaesthesia vs awake mice. A large number of astrocyte genes are dysregulated. B. C.  
Expression of genes upregulated by 24h light stimulus is overall suppressed by 
anaesthesia and vice-versa (p<0.001, 2-way ANOVA). C. Genes significantly changed 
(Deseq2 p_adj<0.05) in both light-stimulus and anaesthesia demonstrate correlation 




 Anaesthesia induces changes in pro-survival and pro-death CNS 
transcriptional pathways.  
 
Some of the activity-driven genes that were dysregulated by anaesthesia were 
activity-regulated genes that are known to have a key role in protecting CNS 
cells from cell-death. These are well established genes that are driven by 
neuronal activity which increase neuronal resilience and inhibit apoptosis 
(Léveillé et al., 2010; Bell and Hardingham, 2011). Anaesthesia suppresses 
activity-regulated inhibitor of death (AID) genes and increases activity-
suppressed pro-apoptotic genes (Figure 4.11A). In fact many of the genes 
essential in both the intrinsic and extrinsic apoptosis pathways are significantly 






































































































































































Figure 4.11 - Anaesthesia results in an increased vulnerability 
transcriptional signature. A. 6h anaesthesia significantly decreases 
expression of activity-induced inhibitor of death (AID) genes and 
increases apoptotic genes (N=5 awake and anaesthetised, ***p<0.001 
two-way ANOVA). B. A large number of genes in both intrinsic and 
extrinsic apoptotic pathways are significantly upregulated by 
anaesthesia. Circled in red are all genes upregulated by anaesthesia 
with Deseq2 p_adj <0.05. 
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Given the strong dysregulation of survival and pro-death genes, I investigated if 
these transcriptional changes had a functional consequences on CNS apoptosis.  
Activation of Caspases 3 and 7 represents the common step in the intrinsic and 
extrinsic apoptosis pathways. I measured protein levels of Caspase 3 (inactive) 
and cleaved-caspase 3 (active) using western blot, finding (consistent with the 
transcriptional changes observed) significantly increased caspase 3 protein 
levels in brains from mice anaesthetised for 6h vs awake mice (Figure 4.12B).  
However, there was no increase in levels of the activated cleaved-caspase 3 
(Figure 4.12C). I next looked at functional caspase 3/7 activity by using a 
caspase activation luminescence assay (Caspase 3/7 Glo). Whilst a good 
induction of apoptosis in positive control samples was confirmed, there was no 
increase in caspase 3/7 activity in anaesthetised vs awake brains (Figure 
4.11D).  
Taken together, these data suggest that prolonged anaesthesia alters 
transcription to boost the apoptotic potential of CNS tissue but without actual 
increase in apoptosis. This might lead to a primed CNS that demonstrates 






























































































Figure 4.12 - Anaesthesia primes apoptotic pathways in the CNS but does not 
increase apoptosis. A  Example Western blot for caspase 3 and cleaved caspase 3, with 
quantification of band-densities. Positive control samples were cultured cells exposed 
to 24h of 100 nM staurosporin, a potent inducer of apoptosis. B, C. Quantification of 
Western blots. 6h anaesthesia increases absolute caspase 3 but not cleaved caspase 3 
levels (N=3 awake and anaesthetised, *p<0.05, two-tailed t-test vs awake mice or 
negative apoptosis control). D. Caspase Glo 3/7 functional caspase activity assay finds 
no change in apoptosis between anaesthetised and awake animals (N=3, * p<0.05, 
unpaired two-tailed t-test vs awake mice or negative apoptosis control).  
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 Using transcranial electrical stimulation to rescue anaesthesia-
induced changes.  
 
Finally, I wanted to determine whether it was possible to reverse transcriptional 
changes induced by anaesthesia by enhancing synaptic activity. This would 
reveal which set of genes are indeed being altered by anaesthesia due to its effect 
on suppressing neuronal activity vs genes that were changing due to other 
consequences of anaesthesia. In addition, the ability to reverse anaesthesia-
mediated effects on activity-dependent CNS prosurvival and death pathways 
would useful for possible future therapeutic strategies.  
I decided that the optimal method for enhancing electrical activity in the brain 
would be to use non-invasive transcranial electrical stimulation (NTES). NTES 
has the benefit of avoiding damaging surgical interventions that may alter gene-
expression. It is a well-established technique in humans and animals ( 
Matsumoto and Ugawa, 2017) and has been shown to enhance neuronal activity 
(Grossman et al., 2017).  
To investigate whether transcranial electrical stimulation could reverse some of 
the transcriptional effects of anaesthesia, I applied NTES to cortical tissue 
during prolonged isoflurane anaesthesia. Stimulation was with a 10Hz electrical 
sinusoidal current (500mA), with a protocol involving 20 mins stimulation, 
followed by 10 mins rest to allow neuronal recovery. This was for 5 stimulation 
episodes for a total time of 100 mins stimulation during the 180 min 
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anaesthesia. CNS RNA was extracted and compared with both a sham 
stimulation (using a 0 mA current) along with RNA from the contralateral non-
stimulated side (Figure 4.13A). The level of expression of three selected IEGs 
(Fos, Bdnf and Arc) were measured using qPCR.  I found NTES enhanced the 
expression of Fos and Bdnf but did not alter levels of Arc. Expression levels were 
boosted both compared to sham stimulation, as well as to the contralateral non-
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Figure 4.13 - Transcranial electrical stimulation reverses 
anaesthesia-induced suppression of activity-dependent genes. A. 
Schematic demonstrating the use of electrical stimulation to locally 
enhance neuronal activity. RNA from this area is compared to 
contralateral non-stimulated tissue and tissue from sham stimulation. 
B. RNA from stimulated cortex extracted and assessed by qPCR. 
Electrical stimulation significantly boosts Fos and Bdnf levels. Arc 
remains unchanged (N=3, *p<0.05 paired two-tailed t-test against 
contralateral non-stimulated side; #p<0.05 unpaired two-tailed t-test 
against sham stimulation).  
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 Chapter discussion 
 Synaptic activity regulates astrocyte transcription in the visual 
cortex 
In this chapter, by combining a light-stimulus paradigm with the TRAP method 
to measure astrocyte-specific gene expression, I have determined that altered 
synaptic activity in the visual cortex drives changes to the expression of a large 
number of astrocyte genes.  
These changes correlate well with data from Chapter 3 using an in vitro 
coculture approach. We found upregulation of a number of genes involved in 
the cAMP pathway as well as genes involved in metabolic flux. However, there 
were some important differences in genes regulated between in vivo and in vitro 
datasets. The number of metabolic genes upregulated is much smaller. And 
there are some genes that are regulated in the opposite direction (for example 
the thyroid hormone activating enzyme Dio2 is upregulated by synaptic activity 
in vitro but down-regulated in vivo).  
Reasons for these differences could be: i) intrinsic differences between in vitro 
and in vivo astrocytes; ii) the presence of other CNS cell-types that modify 
activity-dependent signals; iii) Region-specific differences between visual cortex 
and other cortical astrocytes; iv) differences in the intensity or of the stimulation 
paradigm. Bic vs TTX drug treatment will lead to a much stronger difference in 
synaptic activity than light vs dark in the visual cortex, and this may account for 
transcriptional changes between the two approaches; v) Differences in levels 
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between transcribed mRNA (measured in vitro)  and translated mRNA 
(measured by TRAP in vivo). This is discussed and addressed in more detail 
below.  
The findings correlate well with other studies that have looked at how CNS 
activity may influence astrocyte gene expression in vivo. A recent study by the 
Greenberg group examined a limited set of astrocyte genes determined by single 
cell-sequencing of mouse visual cortices exposed to 1 h and 4 h of light stimulus. 
Due to the limitations of single-cell sequencing, and the fact that sequencing is 
only possible to a much lower depth due to the number of cells involved, they 
found changes in 32 astrocyte genes. My data agrees well with the findings of 
this study. I found approximately 80% overlap with the genes uncovered in that 
study and have further expanded the data-set by finding approximately a 
thousand more genes that are altered by light exposure.   
One interesting finding was that we found that many of the activity regulated 
astrocyte genes are those that are found to be reduced in brains taken from aged 
vs adult mice (2 y vs 4 month). This could be due to : i) Reduced neuronal 
activity due to ageing; or ii) Reduced responsiveness of aged astrocytes to 
neuronal signals. This interesting finding will now require further study, and 
may imply a reduction in activity-induced pathways that ultimately lead to 
increased vulnerability and CNS susceptibility during ageing.  
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 Using mixed-species culture and TRAP to reveal differences 
between cellular transcription and translation.  
One important reason for differences between in vitro and in vivo data could be 
due to differences in measuring total transcription in our previous in vitro 
experiments vs measuring translating mRNA in the TRAP studies. To examine 
the effect of this, I developed a novel approach combining the power of the 
mixed-species coculture approach with the TRAP methodology. This allowed 
me to investigate the non-cell autonomous effects of neurons and neuronal 
activity on astrocyte gene-expression changes at the level of transcription and 
translation.  
I discovered that there was an almost perfect correlation between changes at the 
level of transcription and translation in astrocyte genes that change in response 
to synaptic activity. This appears to make physiological sense:  with acute signals 
to the cell driving transcriptional and translational flux to alter protein 
production and cellular function.  
In contrast, I found that astrocyte genes altered as a result of neuronal contact 
demonstrate reduced correlation between transcription and translation. We 
identified 345 genes that were significantly differentially regulated. Many of 
these genes were related to astrocyte mitochondrial and ATP synthesis activity. 
This reveals an important novel method of non-cell autonomous control that 
regulates gene-expression in astrocytes in response to neurons. The 
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mechanisms by which this translational control occurs is unknown and the 
focus of current study.  
Finally, whilst cellular abundance of proteins has been demonstrated to be 
controlled at the level of translation (Schwanhäusser et al., 2011), there may be 
further differences at the level of translated mRNA and total protein levels in 
astrocytes. Ongoing studies in our lab are now using mass-spectrometry 
proteomics to quantify and understand this difference.  
 
 Anaesthesia reduces neuron and astrocyte activity-dependent 
gene expression 
 
Anaesthesia represents a clinically relevant paradigm when neuronal activity is 
altered for prolonged periods of time. Whilst the exact mechanism of action of 
anaesthetics agents is yet to be established, it is generally considered that they 
globally inhibit neuronal activity by acting as GABA receptor agonists or NMDA 
antagonists (Franks and Lieb, 1994). Furthermore it is well established that 
anaesthesia leads to increased CNS vulnerability in both infants and in the 
elderly, where it can manifest as delirium and post-operative cognitive 
impairment (Leslie, 2017; Bratzke et al., 2018). The mechanisms by which this 
occurs are unknown and I wanted to establish whether prolonged suppression 
of neuronal activity by anaesthesia suppressed neuronal and astrocyte activity-
dependent pathways related to CNS homeostasis and resilience.   
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I found that 6 h exposure to isoflurane anaesthesia led to a wide-spread changes 
in the CNS transcriptional programme. This is not too surprising given the 
diffuse and generalised effects of anaesthesia. Most known immediate-early and 
activity-dependent CNS genes were driven profoundly down by anaesthesia 
confirming that it is a potent suppressor of activity-dependent pathways.  
It has been well-described that neuronal activity is essential for maintaining 
neuronal health, with activity boosting the expression of a gene-programme 
known as AIDs and inhibiting pro-apoptotic neuronal genes (Hardingham and 
Bading, 2003; Léveillé et al., 2010) . Here, I have shown that during anaesthesia 
these pathways are deregulated. Anaesthetised brains demonstrate low levels of 
AIDs and high levels of pro-apoptotic genes.  
I was unable to find evidence of an acute increase in apoptosis using both 
western blot and functional assays for caspase activity. One reason for this might 
be related to timing, with 6 h being too soon for functional apoptosis to have 
begun. Hence we are now undertaking studies to check for apoptotic markers 
48 – 72 h following recovery from anaesthesia. An alternative explanation is that 
anaesthesia does not induce apoptosis per se, but by switching of activity-
dependent protective pathways, primes the brain for apoptosis, leaving it more 
vulnerable to secondary insults.  
This explanation fits well with clinical observations. Many patients can undergo 
anaesthetic procedures with no evidence of long-term neurological sequelae. 
However, patients with already injured brains (due to dementia or ageing) or 
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those exposed to a secondary insult (such as hypoxia or inflammation) are at 
much higher risk of demonstrating delirium and neurological consequences 
following prolonged anaesthetic episodes.  
Finally, I utilised non-invasive transcranial electrical stimulation (NTES) to 
increase neuronal activity during anaesthesia. The exact mechanism by which 
NTES alters neuronal activity is poorly understood, but it is thought to cause 
generalised network synchronisation (Roche, Geiger and Bussel, 2015). It is a 
technique that is routinely used in humans and has been suggested to confer 
neuroprotection and improve outcomes in several conditions.  
In the preliminary work outlined here, I have found that exposure to NTES 
partially rescued the anaesthesia induced effects on activity-regulated genes. 
This gives confidence that some of the transcriptional changes described above 
are indeed due to anaesthesia-mediated suppression of synaptic activity rather 
than other non-specific effects of anaesthesia. Further work is now required to 
determine the ideal frequency and duration paradigm of NTES that induces the 
maximum rescue of gene-expression changes. It is also required to test whether 
NTES has a functional change with regards to apoptotic markers and cognitive 
outcomes.  
 Limitations and future work. 
The TRAP methodology used to investigate cell-type specific gene expression 
has some limitations common to all methods that attempt to separate cell-type 
gene expression: namely that of off-target contamination. Utilising our mixed-
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species coculture approach, and by analysing the amount of rat reads that we 
got in our samples, we were able to calculate this contamination to be at 12(+/-
0.37)%.  
There are also a few specific limitations. EGFP expression is linked to expression 
of the Aldh1l1 gene, which is assumed to be astrocyte-specific. Whilst Aldhl1l1 
is considered to be the best marker (Srinivasan et al., 2016) for distinguishing 
astrocytes from other cell-types in the CNS, it is also expressed in low amounts 
in oligodendrocyte precursors and neural stem cells (Foo and Dougherty, 2013). 
This may mean that some of the gene-expression changes detected may reflect 
contamination from these alternative cell-types.  
Furthermore, the approach pools mRNA from all astrocytes in the cortex and 
hence assumes their response to be heterogeneous. It is known that astrocytes 
demonstrate regional and functional differences (Zamanian et al., 2012; 
Bayraktar et al., 2018) and this method will not enable investigation of these 
differences.  
The light stimulus paradigm has some important limitations. Even in darkness, 
there is some spontaneous retinal activity  (Colonnese, Shen and Murata, 2017). 
Furthermore, it is known that the visual cortex receives innervation from other 
cortical areas (Macaluso, Frith and Driver, 2000). This means that (especially in 
rodents) darkness does not mean the complete absence of neuronal activity and 
will reduce the sensitivity of detecting activity-induced changes. Furthermore, 
altered light dark cycles will have other non-specific effects, for example on 
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circadian rhythm and motility. Therefore confirming findings using an 
alternative stimulation paradigms such as whisker stimulation or auditory 
stimulation would help augment and support the findings in this chapter.  
Finally, an important limitation to consider with all transcriptomic studies is 
that mRNA levels may not necessarily correlate with protein levels. The TRAP 
methodology extracts actively translating mRNA, and hence would be expected 
to correlate more closely with changes in cellular protein abundance and 
function as compared with measurement of total cellular. In fact cellular 
abundance of proteins has been demonstrated to be controlled at the level of 
translation (Schwanhäusser et al., 2011). However ongoing proteomic and 
functional studies in our lab are investigating whether changes in astrocyte 
translating mRNA levels correlate with changes in protein and function.  
 
 Chapter conclusion 
The studies in this chapter support that synaptic activity alters astrocyte 
transcription using in vivo experimental approaches.  Anaesthesia (a potent 
suppressor of synaptic activity), has wide-spread consequences on CNS and 
astrocyte transcription, reducing expression of CNS survival genes and boosting 
apoptotic genes. Combined, these transcriptional changes may lead to increased 
anaesthesia-related CNS vulnerability, and dysregulation of these pathways may 
contribute towards the increased risk of neurological dysfunction clinically 














on astrocyte transcription 
and phenotype.    
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 Chapter Introduction 
In the previous two chapters, I have described the manner and extent to which 
astrocyte transcription and function are regulated by an important physiological 
signal: neuronal synaptic activity. The next natural question that I aimed to 
address was whether astrocyte transcriptional pathways are disrupted in the 
context of neurodegenerative disease.  
As expanded in section 1.3 of the thesis introduction, the role of astrocytes in 
neurodegeneration is complex and incompletely understood. They are proposed 
to play roles as upstream modulators and downstream effectors of 
neurodegenerative pathology (Phatnani et al., 2015; Radford et al., 2015). 
Recent studies have identified heterogeneity in the astrocyte response to acute 
injury and disease, with the capacity to play both neurotoxic and 
neuroprotective roles (Zamanian et al., 2012). Whilst this response 
encompasses a complex and broad spectrum of different roles, the 
transcriptional responses have been divided into two groups: A1 vs A2 
responses (Liddelow and Barres, 2017). Whilst this binary polarisation is an 
oversimplification of a multifaceted astrocyte response, it serves as a useful 
template to discuss broadly neurotoxic vs neuroprotective consequences of 
reactive astrocytosis.   
A1 responses were discovered in response to inflammatory stimuli and are 
considered generally neurotoxic. For example, A1 responses involve 
upregulation of complement cascade genes; to be destructive to synapses and 
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to have neurotoxic effects. In contrast, an alternative A2 response was identified 
in astrocytes profiled from brains exposed to ischaemic injury. These astrocytes 
demonstrated upregulation of neurotrophic and antioxidant pathways, 
demonstrating a response considered broadly neuroprotective.  
Most neurodegenerative conditions involve a complex interplay of a number of 
downstream cellular and molecular pathological processes. These include 
metabolic dysfunction; free-radical damage; vascular compromise; 
inflammation; and ultimately cell-death (De Strooper and Karran, 2016). It was 
unclear to what extent these processes would influence astrocyte phenotype, 
and to what extent the response from astrocytes would be neuroprotective vs 
neurotoxic in the context of dementia. Specifically, we wished to investigate 
how the disease processes involved in dementia alter the balance of one or both 
of the A1 neurotoxic vs A2 neuroprotective transcriptional responses.  
To address the above, I utilised the P301S transgenic mouse - a model of human 
tauopathy and frontotemporal dementia (FTD).  The P301S mutation is a 
familial mutation on chromosome 17 (Sperfeld et al., 1999) that leads to the 
substitution of proline with serine at amino acid position 301 of the human tau 
protein. This increases hyper-phosphorylation of mutant tau, causing 
aggregation and accumulation. Patients with the P301S mutation develop early-
onset FTD and corticobasal degeneration (CBD) in their 20s and 30s.  
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 The P301S transgenic mouse (first described by Allen et al., 2002) sets out to 
model human tauopathy. It drives the expression of the mutant human-tau gene 
with the P301S substitution, under the neuron-specific Thy1.2 promoter.   
The phenotype of the mouse has been well characterised and described 
(Hampton et al., 2010).  The region of the CNS that exhibits greatest 
phosphorylated tau accumulation and hence neurodegeneration is the spinal 
cord. Neurodegeneration also has been characterised in superficial layer 1 and 
2 specific frontal and motor cortex. Regions of neurodegeneration demonstrate 
essential pathological features of tauopathies, including accumulation of 
phosphorylated tau filaments (Figure 5.1A) leading to progressive neuronal 
loss (Figure 5.1 B, C).  Synapse loss and neuronal loss begin at 10 weeks of age, 
and mice begin to exhibit weightless and hind-leg paralysis by 18-20 weeks. The 
functional effects of neurodegeneration can be tested by horizontal bar grip 
strength testing (Fig 5.1F).  Strengths of the P301S transgenic mouse as a model 
for FTD are that it mimics progressive, region-specific, tauopathy-induced 
neurodegeneration along with associated vascular and inflammatory responses.  
In this chapter, I describe studies investigating CNS and astrocyte-specific 
transcriptional consequences of tauopathy-induced neurodegeneration in the 
P301S transgenic model. By crossing these mice with the astro-TRAP line, I was 
able to study effects of tauopathy-induced neurodegeneration on astrocytes at 
end-stage of neurodegeneration.  These studies revealed that astrocytes 
undergo changes in both neurotoxic and neuroprotective astrocyte signatures. 
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Finally, I proceed to describe how boosting a specific aspect of the 
neuroprotective A2 response (by driving astrocyte-specific activation of Nrf2, 
the master antioxidant cellular regulator), reversed both transcriptional and 




Figure 5.1 - The P301S mouse as a model for focal progressive 
neurodegeneration. (Data taken from experiments carried out by members of 
Chandran lab group). A. Hyper-phosphorylated tau accumulates in the cortex and 
spinal cord. B, C. Staining for neurons using the neuron-specific marker ChAt 
(Cholinesterase Acetyl Transferase) reveals neuronal loss at 20 weeks D.  Neuron 
loss is associated with synapse loss. E.  Spinal cord neurodegeneration is the most 
severe phenotype of the model leading to progressive hindleg paralysis F. This can 
be functionally measured using the horizontal bar grip test, which reveals a 






















































































 Tauopathy induces CNS transcriptional changes consistent with 
neurodegeneration and inflammation.   
To investigate the consequence of tauopathy-induced neurodegeneration on 
total CNS transcription, I extracted RNA from superficial frontal cortex and 
spinal cord from P301s mice vs control mice and analysed the transcriptional 
changes using RNA-sequencing. Tissue was extracted at 20 weeks, when mice 
exhibit severe neurodegeneration. Transcriptomic analysis was carried out on 
extracted cortical or spinal cord total CNS tissue (utilising the input samples 
from TRAP analysis) using RNA-seq.  
As predicted, we confirmed that P301S mice exhibited wide-spread 
transcriptomic changes in both the cortex and spinal cord (Figure 5.2 A, B) at 
20 weeks vs WT control mice.  A larger number of genes are changed in the 
spinal cord vs the cortex, consistent with the increased amount of 
neurodegeneration observed in this area.  
The transcriptomic changes demonstrated an increased inflammatory 
signature. Gene-ontology analysis for gene-sets that are significantly 
upregulated or downregulated reveals upregulation of gene-sets associated with 
inflammation and down-regulation for genes associated with neuronal function 
(Figure 5.2C). Utilising cell-type specific gene markers (those from Ye Zhang et 
al., 2014 which are >5 fold enriched in a particular cell-type), I examined which 
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cell-types had the greatest number of transcriptomic changes. This revealed an 
upregulation of a large number of microglia-specific genes (Figure 5.2 D).  
Overall these data suggest increased inflammation and decrease in neuronal 
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Figure 5.2 - Tauopathy induces wide-spread changes to the total 
CNS transcriptome.  A, B. Pre-TRAP input samples (containing mRNA 
from all cells) were analysed by RNA-seq. A large number of genes are 
significantly upregulated and downregulated. The spinal cord (SC) 
demonstrates greater transcriptomic changes than cortex (Cx) 
consistent with the greater neurodegeneration seen in this area (SC-
WT:N=4, SC-P301S: N= 4, Ctx-WT: N=4, Ctx-P301S: N=3). C. Gene-
ontology analysis reveals significant upregulation of inflammatory 
pathways (red) and downregulation of neuronal activity and function 
pathways (blue). D. The largest number of cell-type specific markers 
(#from Ye Zhang et al., 2014 which are >5 fold increased in a particular 
cell-type over other cell-types) that change are from microglia, fitting 
with the increased inflammatory signature present.  
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 Transcriptional changes in the P301S transgenic mouse correlate 
with those in human FTD.  
To understand how well the P301S transgenic mouse modelled human 
tauopathy and frontotemporal dementia (FTD), I compared the transcriptomic 
changes from the above study to transcriptomic data obtained from human 
post-mortem samples. These utilised post-mortem brain samples from the 
superior temporal gyrus (STG) from patients with FTD and non-affected 
controls.   Patient characteristics are summarised in Table 5-1. A large number 
of patients in the FTD group (12/15) exhibited the tau-specific 10+16 mutation. 
This is a common human tau mutation that results in abnormal alternative 
splicing and an increased rate of inclusion of exon 10. This increases the 
proportion of four-repeat (4R) tau isoforms leading to early onset FTD (Hutton 
et al., 1998).  
 
Table 5-1 – Patient characteristics of human post-mortem 
samples 
 Control group FTD group 
Sample N 21 15 
Sex (% Female) 75% 71% 




RNA extraction from post-mortem brains and sequencing of human post 
mortem samples was carried out by Paul Baxter and Jamie Mcqueen from the 
Hardingham and Spire-Jones groups.  
Comparison of the transcriptional data from the P301S mouse with that from 
Human FTD samples reveals that there is strong overlap in gene-sets (Figure 
5.3). Genes that are found to be both significantly changed (Deseq2 p_adj <0.05, 
>1.3 fold upregulated or downregulated) in the spinal cord of P301S mice are 
also significantly changed in human FTD post-mortem brain samples.  
Transcriptional changes between P301S cortex and human FTD samples do not 
correlate. This may be due to the less severe neurodegeneration seen in the 
cortex vs spinal cord, which may not match as well with the level of 
neurodegeneration seen in end-stage post-mortem FTD brain samples.  
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Figure 5.3 - Transcriptional changes in the spinal cord of p301S 
tauopathy mouse model correlates with those found in human 
FTD.  A,B. Expression levels of genes that were significantly 
(p_adj<0.05, fold change >1.3) changed in the spinal cord of P301s vs 
WT mice at 20 weeks was compared in samples extracted from post-
mortem human STG from healthy controls and those diagnosed with 
FTD. Gene-expression changes in FTD correlate with those seen in 
P301S spinal cord. C.D. Similar to above but for cortex, and this time no 
correlation found.   (P301S and control mice- N = 4 each group. Human 





 Neuronal tauopathy and neurodegeneration drives changes to 
astrocyte transcription. 
Next, I investigated how tauopathy-induced neurodegeneration specifically 
altered astrocyte transcription. By crossing the P301S mouse with the astro-
TRAP line, I was able to use the TRAP method to isolate astrocyte-specific 
changes in gene-expression. Mutant tau expression in the P301S line is 
expressed in a neuron-specific manner. Therefore astrocyte transcriptional 
changes would occur via non-cell autonomous consequences of tau-mediated 
neurodegeneration, rather than a direct toxic effect of mutant tau expressed in 
astrocytes.  
Astrocyte specific gene expression was assessed by TRAP-sequencing spinal 
cord and cortex samples from 20 week old mice, and comparing to WT control 
mice. I first confirmed that TRAP was able to successfully enrich astrocyte 
mRNA from older brains experiencing neurodegenerative changes, ensuring  
enrichment of astrocyte-specific markers and depletion of other cell-type 
markers between TRAP and pre-TRAP input samples. 
Tauopathy-induced neurodegeneration alters a large number of astrocyte genes, 
with changes greater in spinal cord vs cortex, fitting with the more severe 


































































































Figure 5.4 - TRAP-seq reveals that tauopathy-inducd neurodegeneration 
induces wide-spread changes to astrocyte transcription. . TRAPseq used to 
isolate astrocyte-specific transcriptional changes in P301S vs WT mice at 20 
weeks in A. spinal cord and B. Cortex. Spinal cord demonstrates a greater 
number of genes significantly altered (p_adj <0.05) vs cortex.  (Spinal cord: N=4 
P301S, N=4 control. Cortex:  N = 4 P301S, N=3 Control).  
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 Astrocyte activity-dependent genes are suppressed by 
neurodegeneration.  
Given the marked neurodegeneration and synapse loss seen in FTD, I was 
interested in whether there was any consequence on synaptic activity-
dependent astrocyte genes identified in chapters 3 and 4.  I compared the 
expression of genes altered in vivo by 24h light with those changed in the P301S 
model. I found that astrocyte genes that are both up and down-regulated by 
light-exposure are significantly dysregulated in P301S vs WT spinal cord 
(Figure 5.5).  Overall, these data present a picture of activity-dependent 
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Figure 5.5 - Neuronal tauopathy drives changes to astrocyte 
activity-dependent genes. A.  Activity-regulated astrocyte genes 
(upregulated by 24h light v dark exposure) are significantly down-
regulated in the spinal cords of P301S mice at 20 weeks. B. Conversely, 
activity-suppressed genes (downregulated by 24h light v dark) are 
significantly increased in P301s vs wt spinal cord at 20 w. (N = 4 
animals P301s and WT. Red and blue bars are significantly changed 
genes with deseq2 p_adj < 0.05. Overall p-value calculated using 2-way 
ANOVA). C. The data in A and B is re-presented as percentage overlap 
of gene-sets between genes up and down-regulated in P301S vs WT, 
with genes up and down-regulated by 24h light stimulus (***p<0.001 
Fishers exact test).  
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 Tauopathy induces reactive astrocytosis – promoting both 
neurotoxic “A1” and neuroprotective “A2” signatures.  
Next, I investigated whether astrocytes in the P301S model demonstrated 
transcriptional changes for reactivity. In  Zamanian et al., 2012, reactive 
astrocyte transcriptional changes were profiled in response to two different 
acute injury models – lipopolysaccharide (LPS) injection and middle cerebral 
artery occlusion (MCAO). The Zamanian et al. study identified two distinct 
populations of reactive astrocytes along with their transcriptional signatures. 
“A1” astrocytes, found in response to LPS challenge, were shown to have a 
neurotoxic effect. A2 astrocytes, found to increase in response to MCAO, were 
neuroprotective. I identified genes that are considered specific cell-markers for 
A1 vs A2 astrocytes (Liddelow et al., 2017), along with an expanded panel 
generated by considering genes that change > 4 fold to LPS stimulation (A1) or 




Table 5-2 - Reactive Astrocyte Genes: Genes that have been used in 
key papers (Liddelow et al., 2017, Clarke et al., 2018) as representing 
specific markers of reactive A1 and A2 astrocytes. List derived from 
Zamanian et al, 2012, as those that are highly upregulated (>7 fold) in 
response to both LPS and MCAO injury (pan-reactive), or selectively 
upregulated (>10 fold) to either LPS injury alone (A1) or MCAO injury 




Gfap S1pr3 Cxcl10 Serpina3n Cp Steap4 Lcn2 
Hspb1 Timp1 Osmr Vim Cd44 Aspg  
A1 
Genes 
H2-D1 Srgn Ggta1 Fkbp5 Gbp2 C3 Amigo2 
H2-T23 Serping1 Iigp1 Psmb8 Fbln5 Ugt1a1  
A2 
Genes 
S100a10 Sphk1 Cd14 Tm4sf1 Ptgs2 Ptx3 Clcf1 




Table 5-3 -  Expanded panel of reactive astrocyte genes. Genes from 
Zamanian et al, 2012 that are upregulated >4 fold in response to LPS 
and MCAO injury (pan-reactive expanded), or either LPS injury alone 

















 Galntl2 Tspan4 Rhoj Serping1 Cp Cd44 Cxcl2 
Mpa2L Nek6 Cpne8 Hpgd Timp1 Iigp1 Ifi202B 
Gfap Vim Serpina3N Usp18 Cd14 Ggta1 Slc10A6 
S100A10 Cdkn1A Gbp3 Oasl2 S1Pr3 Procr Chil1 
Hspb6 Spp1 Tagln2 Lrg1 Cxcl10 Thbs2 Synpo 
Gap43 Sphkap Aspg Slc39A14 A2M Osmr Tgm1 













C1S Irgm1 Srgn Il1R1 Tspo Xaf1 Crispld2 
Fbl5 Kctd1 Dcn Parp14 Sorbs1 Endou Slc43A3 
Hsp1 Acsl5 Tgm2 Plin4 Gsr Tapbpl Slc1A5 
Il13Ra Gpx3 Angpt1 Ifi44 H2-D1 H2-T23 C1Ra 
Pmsb8 Sulf2 Gbp2 Tgtp1 Tapbp Amigo2 Tlr2 
Olfm1 Nfasc Sema4C H2-Q6 H2-K1 Fkbp5 Trim30A 
B2M Igtp Zc3Hav1 Saa3 Tnfaip2 Psmb9 H2-T10 













Agpat9 Gpx1 Fscn1 S100A11 Arpc1B Anxa2 Nop58 
Cdbpd Mrps6 Odc1 Gadd45A Ctps Tnfrsf12A Plp2 
Chl4 S100A6 Klf6 Hmox1 Bcat1 Sphk1 Cav1 
Eii2 Asns Txnrd1 Vgf Tubb6 Fam129B Dpysl3 
Hmga Nhp2 Lmna Eif1A Anxa3 Prss23 Klhdc8A 
Jub Esd Ociad2 Gadd45B Chac1 Ctgf Tm4Sf1 
Lass6 Nupr1 Syt4 Lrrfip1 Col6A1 Msn Klf5 
Odz2 Lgals1 Anxa7 Rnf19B Hspb1 Mthfd2 Sbno2 
Tuba1A Srxn1 Pcbp3 Camk2D Ccnd1 Bdnf Rnf125 
Zwint Lrrc59 Mcl1 Litaf Mest Actn1 Gcnt2 
Uck2 Lgals3 Il13Ra1 Tlr4 Tgfbi Vcan Adam12 
Lonrf1 Slc7A1 Akap12 Pvr Fosl1 Il6Ra H19 
Tgif1 Adamts4 Ahr Cdt1 Bdkrb2 Cdk6 Stx11 
Ecm1 Igfbp3 Adamts5 Sulf1 Spata13 Met Clcf1 
Neto2 Akr1B8 Tmem74 Cacng5 Slc44A3 Gdf15 Flnc 
Anxa1 Socs3 Fosl2 Slc5A3 Col12A1 B3Gnt5 Hmga2 
Btg3 Flna Gch1 Cyp1B1 Shisa6 Thbs1 Ifi203 
Nav2 Thbd Nes Pla2G4A Emp1 Steap1 Pappa 
Grb10 Cd24A Ahnak Pde3B Ahnak2 Fgl2 Eda2R 
Col6A2 Olfml3 Ptgs2 Lif Ch25H Il6 Ccl2 
Serpine1             
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I used the above gene-panels to investigate how the reactivity profile of 
astrocytes change in response to P301S induced tauopathy. Pan-reactive 
markers are significantly upregulated in P301S cortex and spinal cord at 20 
weeks (Figure 5.6A). I found that in P301S spinal cord there is a significant 
increase in both A1 and A2 transcriptional signatures. In P301S cortex, the 
changes are much less marked. In the cortex, there is a significant increase in 
A2 markers but A1 markers but do not achieve significance as a group (Figure 
5.6 B, C).  
One of the key pathways considered to form part of the neuroprotective A2 
response is the upregulation of astrocyte antioxidant capacity.  Indeed two key 
Nrf2-target antioxidant genes Hmox1 and Srxn2 are part of the expanded panel 
of A2 genes. Utilising a panel of Nrf2 activator genes that have been identified 
to be Nrf2 responsive (work in the Hardingham lab utilising Nrf2 KO mice), I 
found a marked Nrf2 activation signature in the P301S mouse (Figure 5.6D).   
Taken together, these data demonstrate that astrocytes in the P301S model 
undergo transcriptional changes consistent with reactivity. They demonstrate 
upregulation of both neurotoxic and neuroprotective transcriptional signatures, 
including evidence for upregulation of the Nrf2 responsive antioxidant gene-
response.  
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Figure 5.6 - P301S tauopathy induces a pan-reactive astrocyte 
signature, consisting of both A1 neurotoxic and A2 
neuroprotective responses. A.  Spinal cord and cortex from P301S 
mouse demonstrates upregulation of pan-reactive astrocyte markers. ( 
***p<0.001, 2-way ANOVA) B.  Astrocytes from p301S spinal cord 
demonstrate significant upregulation of A1-specific genes as well as an 
expanded A1 panel. Cortex is tending towards upregulation but does 
not achieve significance. (Ctx: p = 0.37, *** p <0.001, 2-way ANOVA). C. 
Both cortex and spinal cord astrocytes from p301S mice demonstrate 
significant upregulation in A2 transcriptional signatures (*p = 0.04, *** 
p < 0.001, 2-way ANOVA). D. P301S tauopathy boosts Nrf2 target genes 
in both cortex and spinal cord (*p = 0.012, *** p < 0.001, 2 way ANOVA).  
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 Transcriptional and synaptic changes in the P301S mouse 
precede functional loss.  
The transcriptional changes described above represent the end-stage of 
neurodegenerative disease. Work from our lab has demonstrated that synapse 
and neuronal loss precede motor-deficits in the P301S model and can be 
detected as early as 12 weeks.  
Therefore I investigated whether the transcriptional changes were present at the 
earlier time point of 12 weeks and how these compared to those seen in later 
disease. This knowledge would be important with regards to timing 
interventions for reversing and influencing disease trajectories. RNA was 
extracted from motor cortex from P301S mice at 12 weeks of age and gene-
expression analysed with RNA-sequencing. This revealed cortical 
transcriptional changes (total RNA) at 12 weeks, which precedes functional 
impairment(Figure 5.7A). Cortex transcriptional changes at 12 weeks correlate 
well with transcriptional changes found in the cortex at 20 weeks ( 













































































Figure 5.7 - Transcriptional changes observed in the P301S cortex 
at 12 weeks. A.  RNA-sequencing reveals changes in multiple genes at 
12 weeks in the cortex. B. Genes that are changed at 12 weeks correlate 
well with cortex genes that are found to be changed in the cortex at 20 
weeks (p<0.001, Spearman’s rank correlation. Cortex 20 weeks: N = 3 





 Nrf2 over-expression reverses transcriptional and functional 
consequences of tauopathy.  
A key element of the neuroprotective response upregulated in astrocytes in the 
P301S mouse was the increase in Nrf2 target gene-expression. These genes form 
part of the A2 neuroprotective response and are involved in increasing astrocyte 
antioxidant capacity – a key cyto-protective pathway in the brain.  
We hypothesised that this response represented an adaptive-protective 
response by astrocytes, but that it was insufficient or too late to confer total 
neuroprotection. Subsequently progressive tau accumulation and inflammation 
in end-stage disease induces a switch towards a more neurotoxic A1 phenotype 
which worsens neurotoxic effects.   
Therefore we set out to investigate whether boosting the adaptive-protective 
astrocyte Nrf2 response might confer neuroprotective benefit. This was 
achieved by crossing the P301S transgenic mouse with the GFAP-Nrf2 
transgenic line. This line over-expresses Nrf2 specifically in astrocytes driven by 
the GFAP promoter. GFAP is a marker of astrocyte reactivity, ensuring that the 
Nrf2 response is focused on areas of neurodegeneration.  
We confirmed successful upregulation of antioxidant gene expression in the 
cortices of P301S-Nrf2 mice (Figure 5.8). Nrf2 over-expression does not change 
the levels of tau or total astrocyte numbers in P301S mice, but there is a reduced 









































































Figure 5.8 - P301S mice crossed with the GFAP-Nrf2 line 
upregulate expression of Nrf2 antioxidant target genes in the 
cortex. Levels of known Nrf2 target genes were measured in the cortex 
of P301s mice vs P301S-Nrf2 mice. As expected, there was a significant 
increase in antioxidant target gene expression (P301S: N=3, P301S-
Nrf2: N=5 ***p<0.001 2-way ANOVA).  
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Strikingly, we found that over-expressing Nrf2 in astrocytes in P301S mice 
strongly reversed the transcriptomic changes seen vs WT mice (Figure 5.9 A, 
B). Many genes that are upregulated or down-regulated by tauopathy-induced 
neurodegeneration in the CNS demonstrated a rescue in their expression in 
P301S mice crossed with GFAP-Nrf2. Selected genetic markers involved in 
neurogenesis and synaptogenesis, which are found to be down-regulated in 
P301S vs wt cortex, are restored (Figure 5.9 C). Genes that are dyregulated and 
overlap between human FTD and P301S datasets are also restored by over-
expression of Nrf2 (Figure 5.10).  
Finally, we confirmed that the rescue of transcriptional changes translated into 
a functional rescue in P301S mice.  Nrf2-expressing P301S mice had 
significantly reduced neuronal loss (Appendix Figure 7.5A) and Nrf2 over-
expression led to a delay in the development of functional deficit, as assessed by 
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Figure 5.9 - Over-expression of astrocyte-specific Nrf2 reverses 
transcriptional changes induced by p301S tauopathy. A Expression 
of genes that are significantly upregulated or downregulated (1.3 fold 
change, p_adj <0.05) in P301S vs WT are reversed in P301S-NRf2 mice.  
B.  Nrf2 overexpression significantly reverses genes that are 
upregulated or down-regulated in P301S mice vs wild-type 
(***p<0.001 - 2-way ANOVA, control: N= 6, P301S: N = 3, P301S-Nrf2: 
N = 5). C Nrf2-overexpression boosts a large number of genes related 
to synaptogenesis and neurotrophic effects that are suppressed P301S 
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Figure 5.10 - Genes that are found to be changed in both human 
FTD samples and p301S mice are also genes that are found to be 
rescued by Nrf2 over-expression. The subset of genes that are 
upregulated (A) and downregulated (B) in both human FTD samples 
and P301S cortex at 12 weeks are significantly rescued by over-




 Chapter Discussion 
 Tauopathy-induced neurodegeneration is associated with wide-
spread CNS transcriptional changes. 
In this chapter, I have described the transcriptional changes that occur in 
response to tauopathy-induced neurodegeneration, in both total CNS tissue and 
specifically in astrocytes.   
In the P301S mouse model, by 20 weeks there is extensive neuronal cell death 
and neurodegeneration in the spinal cord and superficial frontal motor cortical 
areas. As expected, these pathological changes were associated with wide-
spread transcriptional changes. The most marked signature was that associated 
with inflammation. Microglia-specific genes were the largest number changed 
and gene-ontology analysis revealed upregulation of several gene-sets 
associated with inflammatory pathways. This fits with current theories 
regarding the key role for inflammation and microglial activation at the end-
stage of FTD (Zhang, 2015).  
We also examined the changes that occur in human FTD samples taken post-
mortem compared to non-affected samples. We found a strong correlation with 
transcriptional changes seen in the P301S model with changes found in post-
mortem tissues.  This strong transcriptional overlap gives confidence that the 
P301S transgenic mouse model recapitulates key pathological processes that 
occur in human tauopathy and FTD, and supports using it in the studies 
outlined in this chapter.  
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 Neurodegeneration promotes a reactive astrocyte 
transcriptional signature consisting of both A1 and A2 responses.  
The studies in this chapter also uncovered how neuronal tauopathy induces 
wide-spread astrocyte-specific transcriptional changes.  A key finding was that 
many of the activity-dependent genes described in previous chapters are 
dysregulated following neurodegeneration. These gene sets are also found to be 
altered in old vs young mice.  Activity-dependent astrocyte genes may become 
altered due to surrounding neuronal death and a possible reduction in the 
activity-mediated signals from neurons. It may also be that reactive astrocytes 
become less responsive to activity-dependent signals. As many of the activity-
dependent genes found previously were shown to be important for CNS 
homeostatic processes, such as metabolism, it is likely that dysregulation of 
these pathways may impair the homeostatic processes in the CNS. This may in 
turn make the tissue more vulnerable and increase subsequent neuronal death.  
Consistent with the current understanding of astrocytes becoming more 
reactive in disease, we found that astrocytes in the P301S model demonstrate 
an increase in a large number of reactivity-associated genes. We have extended 
this understanding and characterised the nature of this reactive response, 
demonstrating how the balance of neurotoxic A1 vs neuroprotective A2 
responses is influenced during the course of the disease process.  
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Our studies reveal that neurodegeneration boosts both neurotoxic A1 and 
neuroprotective A2 reactive astrocyte responses. In the spinal cord, the area of 
greatest neurodegeneration, there is an upregulation of both A1 and A2 
signatures. In the cortex, where there is less neurodegeneration, there is an 
upregulation of A2 but not A1 signatures. One explanation for this is that the 
cortex represents an earlier time-point of neurodegeneration vs the spinal cord. 
A2 responses may be enhanced first, conferring an element of neuroprotection 
in early disease. However, following increased cell-death and increased 
inflammation, astrocytes switch to an A1 response. This enhances neurotoxic 
effects and worsens end-stage neurodegeneration. An important caveat to the 
above finding is that the sample numbers for cortex are less than for spinal cord, 
and this may influence the total number of significant genes identified. We are 
currently obtaining further samples and performing further experiments to test 
the above hypothesis by looking at the A1 vs A2 signatures in cortex and spinal 
cord at earlier time-points.  
 
 Boosting Nrf2 activity in astrocytes confers neuroprotective 
effect. 
We found that a key constituent of the A2 response in the P301S mouse was   
upregulation of the Nrf2 antioxidant response. Antioxidant capacity is a key 
protective role of astrocytes and dysregulation of antioxidant pathways is 
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thought to also play a key role in the end-stage processes of multiple 
neurodegenerative diseases.  
We hypothesised that boosting the antioxidant aspect of the A2 protective 
response would confer neuroprotection. We therefore crossed the P301S line 
with the GFAP-Nrf2 transgenic mouse line. By coupling Nrf2 activation to the 
GFAP promoter, we achieved both astrocyte-specificity as well as ensuring that 
the greatest Nrf2 action occurs in reactive astrocytes at the site of 
neurodegeneration. Over-expressing Nrf2 in this manner led to reduced 
reactive changes in the CNS, and reversed not only many of the transcriptional 
changes seen in P301S mice, but also protected against neuronal loss and 
achieved functional improvement. Mice exhibited a significant delay in 
functional performance deterioration as measured by horizontal bar testing 
between 18-20 weeks.   
Therefore, we have demonstrated that boosting astrocyte-specific Nrf2 offers 
neuroprotective benefits in this model of FTD. This is particularly interesting 
given that in this model tau is expressed in a neuron-specific manner, and 
demonstrates the importance of non-cell autonomous interactions in 
promoting neuronal resilience.  
 Limitations 
It is important to acknowledge the limitations of the P301S transgenic mouse 
as a model for FTD. Firstly, the model is based on the overexpression of a single 
mutant tau gene. Overexpression models lead to very severe and rapid disease, 
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which is different from the typically slower and insidious onset of real dementia. 
Furthermore in the P301S model, the area most affected is the spinal cord. This 
contrasts to human FTD where the main pathological brain region is the frontal 
cortex. However, it is becoming increasingly recognised that FTD overlaps with 
spinal cord diseases such as ALS. The difference in regional expression in our 
model arises from the expression of tauopathy being driven by the Thy1.2 
promoter, which induces this in all neurons throughout the CNS, with disease 
coming on earlier in the spinal cord. This contrasts to FTD which exhibits 
frontal-cortex specific onset of tau-accumulation.  
However, despite these weaknesses, the P301S mouse is a powerful model in 
that it provides a model of region-specific, progressive neurodegeneration. The 
correlation found in transcriptomic changes with actual human post-mortem 
FTD samples gives confidence in utilising this model to answer the specific 
questions that I have set out to address in this chapter.  
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 Chapter Conclusion 
In this chapter, I have used the P301S transgenic mouse model of human 
tauopathy to describe how neurodegeneration drives wide-spread changes in 
astrocyte transcription. These changes include dysregulation of synaptic-
activity regulated genes, and upregulation of both neurotoxic A1 and 
neuroprotective A2 reactive responses. Finally I have described how enhancing 
a key aspect of the A2 response – upregulation of astrocyte Nrf2-mediated 
cytoprotective antioxidant function – confers neuroprotection and delays 
















 Overview of aims accomplished 
The aim of the work described in this thesis was to understand how astrocyte 
transcription and function are controlled by neuronal interactions in both 
normal physiology and following neurodegenerative disease.   
I first described how synaptic activity induces wide-spread transcriptomic 
changes in astrocytes and demonstrated that these lead to an increase in the 
ability of astrocytes to utilise glucose to produce lactate, which can be used as a 
fuel for neurons. This couples astrocyte glycolytic ability to neuronal metabolic 
demands and uncovers a novel pathway by which neurons are able to tune 
astrocytes to regulate metabolic homeostasis in the neuroglial unit.  
I then described the capacity of synaptic activity to regulate astrocyte 
transcription in vivo and investigated how anaesthesia (a potent suppressor of 
neuronal activity) leads to widespread dysregulation of neuronal and astrocyte 
transcription. Transcriptional changes during anaesthesia induce a pro-
vulnerability signature, which may contribute towards neuronal vulnerability in 
the perioperative period.  
Subsequently I investigated the consequences of neurodegeneration on 
astrocyte transcription and phenotype. Using a transgenic mouse model of 
human tauopathy, I described how neurodegeneration alters astrocyte 
transcriptional phenotype. I found that the transcriptional response of 
astrocytes to neurodegenerative disease is complex and heterogeneous, with 
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upregulation of both neurotoxic and neuroprotective responses. Finally, I 
demonstrated that boosting a key aspect of the neuroprotective response 
(activation of the Nrf2 cytoprotective antioxidant pathway) in astrocytes 
enabled transcriptional and functional rescue in this neurodegeneration model.  
 
 Contribution to existing knowledge 
The studies outlined in this thesis add to the growing understanding of the role 
of glia and non-cell autonomous signalling in the CNS in regulating homeostasis 
in health, and describe how these pathways are dysregulated in disease. This 
includes contributing towards published work which was the first complete 
description of how synaptic activity influences astrocyte transcription (Hasel et 
al., 2017). A recently study published (Hrvatin et al., 2018), utilising single-cell 
sequencing of activity-dependent responses of all neural cell-types in the visual 
cortex, has described a limited number of astrocyte genes changing in response 
to light- stimulus. The in vivo studies in this thesis complement this dataset and 
are the first studies specifically investigating how astrocytes alter transcriptional 
pathways in response to neuronal stimuli. Our methodology has revealed many 
more transcriptional targets in astrocytes that are altered by synaptic activity 
(1333 in our study vs total of 24 in Hrvatin et al., 2018). 
We have also established a detailed profile of transcriptional changes that occur 
within the CNS and specifically in astrocytes in response to end-stage 
neurodegeneration.  The concept of astrocytes being both neurotoxic and 
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neuroprotective is an emerging idea (Liddelow and Barres, 2017). Here, we 
demonstrate that the astrocyte response to disease is complex with upregulation 
of both neurotoxic and neuroprotective responses. We have also described the 
novel finding that promoting elements of the astrocyte A2 protective response 
are able to confer neuroprotective benefit in FTD – a finding that complements 
studies that have found boosting Nrf2 (in astrocytes or total CNS) enhances 
neuroprotection in other different neurodegenerative disease models, including 
multiple sclerosis (Bomprezzi, 2015), amyotrophic lateral sclerosis (Vargas et 
al., 2008) and Parkinson’s disease (Jakel et al., 2007).  
 
 Implications for future therapeutic benefit 
The ultimate purpose of the studies in this thesis is to contribute towards our 
understanding of how homeostatic and resilience pathways in the brain are 
disrupted in dementia, with a hope that this understanding may contribute 
towards the development of future therapies. The studies in this thesis have 
highlighted some key putative pathways that form attractive therapeutic 
targets.   
The astrocyte CREB pathway appears to regulate astrocyte activity-dependent 
responses. The studies in this thesis have described how these activity-
dependent pathways are dysregulated with ageing and in neurodegeneration. 
Therefore targeting this transcriptional pathway may maintain and boost 
homeostatic pathways in the brain and enhance resilience during disease.  
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The CREB pathway can be enhanced by drugs that target the cAMP pathway, 
including forskolin and phosphodiesterase inhibitors. In fact, targets of cAMP 
pathway have already been studied in clinical trials for a range of CNS diseases. 
Rolipram (a selective type-4 PDE) was developed as an antidepressant but failed 
phase 3 trials due to severe nausea and gastrointestinal side-effects 
(Fleischhacker et al., 1992). Cilostazol (a PDE3 inhibitor) is currently being 
tested as part of the LACI-2 clinical trial for SVD induced dementia 
(http://www.isrctn.com/ISRCTN14911850). Within this study, the rational for 
using this drug is for cerebral vasculature modulation. PDE-3A is actually 
expressed highest in astrocytes and given the findings in this thesis, it may be 
that any benefit conferred may be via enhancement of astrocyte pathways.  
In this thesis, I have also described preliminary studies utilising non-invasive 
transcranial electrical stimulation (NTES) to boost CNS activity and to reverse 
transcriptional changes seen during anaesthesia.  NTES has already been 
utilised in a number of clinical studies investigating whether it confers benefit 
in depression, schizophrenia and Parkinson’s disease (Bennabi et al., 2014). 
Therefore it would be interesting to investigate if this methodology could offer 
clinical benefit to boost CNS resilience pathways acutely in vulnerable patients 
undergoing sedative anaesthesia, and longer-term in neurodegenerative 
disease.  
Finally, I described how enhancing astrocyte Nrf2 expression confers 
neuroprotection in the P301S model of tauopathy. Whilst these findings will 
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need to be confirmed in other models, they highlight Nrf2 as a putative target 
that could alter disease trajectory in FTD.  
Targeting the astrocyte-specific Nrf2 pathway has been shown to confer 
protection in other neurodegenerative diseases including the SOD1 model of 
ALS (Vargas et al., 2008) and in a - 6-hydroxydopamine injection model of 
Parkinsonism (Jakel et al., 2007).  Targeting Nrf2 in the clinical context has been 
difficult. Many activators are electrophilic compounds and hence extremely 
toxic, and have poor permeability of the blood brain barrier. However, more 
recent classes of drugs have been developed (for example triterpenoid-based 
compounds such as 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO)) 
which have less toxic effects. Examples of current Nrf2 based therapeutics or 
those undergoing clinical trials include: Dimethylfumerate(DMF) for multiple 
sclerosis (Bomprezzi, 2015), omaveloxolone for Fredreich’s ataxia (Trial 
number: NCT02255435) and CuII(atsm) for Parkinsons disease (Trial number: 
NCT03204929). The studies in this thesis are the first to highlight the utility of 
targeting astrocyte antioxidant pathways as way of conferring neuroprotection 
in dementia.  
 
 Limitations of studies and proposed future work 
One of the key limitations of the studies outlined in this thesis, is that they 
consider transcriptomic changes in astrocytes pooled from a large number of 
cells. Therefore, this approach treats all astrocytes as exhibiting the same 
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response to a specific injury or insult. Therefore this approach has not allowed 
me to determine the number, arrangement and organisation of any distinct 
astrocyte populations within our experiments.  
This can be resolved using a number of methodologies. Single-cell sequencing 
will reveal whether there are distinct astrocyte populations in the disease 
models used, and spatial transcriptomic approaches will allow probing of the 
anatomical distribution of these cells. Finally using fluorescence in-situ 
hybridisation (FISH) and RNAscope will allow specific cell-populations of 
astrocytes to be identified.  We are currently carrying out these investigations 
to address this gap in our understanding.  
Finally, this thesis has focused on neuron-astrocyte interactions. However, it is 
important to consider that astrocytes have interactions with all CNS cell-types, 
including microglia, oligodendrocytes, pericytes and brain endothelial cells. It 
is likely that there are yet-unstudied interactions between all these cell-types 
that regulate CNS homeostasis, and have a role to play in CNS dysfunction in 
disease. These complex interactions will only be understood through novel 
methodologies exploiting a combination of approaches. Example methods 
include TRAP-reporter mice driven by specific promoters for the above cell-
types, as well as novel cell-type sequencing and proteomic approaches. 
Understanding the total cell-autonomous and non-cell autonomous 
interactions between the different cell-types in the brain and how these are 
disrupted in disease is a complex and challenging task. However, it would be 
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hoped that a more complete understanding of these signals would reveal key 
pathways that could be targeted to protect the brain and improve outcomes for 
patients with dementia.  
 Thesis conclusion 
In this thesis, I have described studies demonstrating how astrocyte 
transcription is controlled by neuronal signals to regulate CNS metabolic 
homeostasis in health, and how astrocyte transcription is altered in a model of 
dementia. These involve transcriptional changes to both neuroprotective and 
neurotoxic astrocyte pathways and I have demonstrated that boosting beneficial 
astrocyte-functions confers neuroprotective benefit.  
Dementia research has traditionally focused on neuronal pathology. Taken 
together, the studies in this thesis support emerging interest in also targeting 




 Supplementary Figures 
 Electrophysiological confirmation of enhanced neuronal firing 
achieved with pharmacological paradigm. 
 
Figure 7.1 (Appendix) - Data collected by Sean Mackay. Figure 
from Hasel et al., 2017. Sample trace showing effects of TTX and 
bicuculline (BiC) stimulation on neuronal firing. Cocultured cells were 
incubated overnight in tetrodotoxin (TTX), to block neuronal firing. 
Cells were then washed in the presence BiC. Whole-cell current-clamp 
(upper) and voltage-clamp (lower) recording of neurons exposed to 
this paradigm confirms resultant increase in burst activity. Scale bar, 
15 mV, 30 s (upper); 50 pA, 30 s (lower) 
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Figure 7.2 (Appendix) - Transcriptional Changes between GFAP-Nrf2 
and WT controls. A. P301SxGFAP-Nrf2 mice demonstrate similar 
upregulation of Nrf2 target genes as GFAP-Nrf2 mice. B. GFAP-Nrf2 vs WT 
expression of genes changed in P301S vs WT mice. This confirms that the 
rescue of genes seen in the P301S mouse is not simply due to upregulation 
or downregulation of genes due to Nrf2 expression, but represents a rescue 
from the P301S effects. In fact, expression of Nrf2 alone changes genes that 
are found to be disrupted in P301S vs wt in the same direction (WT N=6; 
GFAP-Nrf2 N = 5; 2-way ANOVA).  
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 Time-course of synapse and neuronal loss in the P301S model 




















































































Figure 7.3 (Appendix) -  Time-course of synapse and neuronal loss 
in the P301S human tauopathy model. Data collected by Sachin 
Tiwari. A. P301S transgenic mouse exhibits synapse loss at 12 weeks 
before functional changes. P301S mice were crossed with GFP-PSD95 
transgenic line and PSD95 puncta counted. B. Neuronal loss begins at 
12 weeks - assessed by NeuN staining and counting of neurons (* 
p<0.05, unpaired t-test). 
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 Changes to tau-levels and astrocyte numbers with Nrf2-over-


































































Figure 7.4 (Appendix) - Effects of Nrf2 over-expression on tau 
expression and astrocyte cell-numbers at 12 weeks in the P301S 
model. Data collected by Sachin Tiwari. Over-expression of Nrf2 
does not change total tau staining (assessed by AT8 antibody staining) 
or total astrocyte numbers (assessed by staining with anti-Aldh1l1 
staining). Total number of reactive astrocytes (using GFAP staining) 
are reduced (*p<0.05, unpaired t-test).  
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 Rescue of neuronal and functional loss by Nrf2 over-expression 





































































Figure 7.5 (Appendix) - Nrf2 over-expression rescues neuronal 
and functional loss in the P301S transgenic model.  Data collected 
by Sachin Tiwari and Megan Torvell. A. Neuron number assessed by 
NeuN staining and counting. P301S mice demonstrate significantly 
greater neuronal numbers at 12 weeks with astroctye-Nrf2 over-
expression. Differences are the same at 20 weeks. B. Astrocyte-Nrf2 
over-expression rescues functional deficits in the P301S mouse at 18-
21 weeks as assessed by horizontal bar strength-testing (*p<0.05).  
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